var title_f28_52_29504="JXG solitary lesion";
var content_f28_52_29504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical solitary lesion on the abdomen of an infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29504=[""].join("\n");
var outline_f28_52_29504=null;
var title_f28_52_29505="MR post MI parasternal long axis echo with closeup";
var content_f28_52_29505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/62935/palaxzmr_conv.mp4?title=MR+post+MI+parasternal+long+axis+echo+with+closeup\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal long axis view from a 2-D echocardiogram with a close up of the mitral valve (MV) shows a posterior leaflet that has limited mobility and fails to close properly with systole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29505=[""].join("\n");
var outline_f28_52_29505=null;
var title_f28_52_29506="Moyamoya and ischemic stroke";
var content_f28_52_29506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A nine year old boy with moyamoya disease who presented with repeated episodes of transient left hemiparesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Noncontrast head CT scan shows low density area of infarction in the right basal ganglia (arrow). B) MRI T2-weighted image depicting a high signal intensity area in the right basal ganglia and multiple small hyperintense areas in both basal ganglia consistent with infarction. C and D) Selective intra-arterial digital subtraction angiogram (anteroposterior projection) shows severe stenoses of the distal right and left internal carotid arteries. Abnormal network of blood vessels (puff of smoke or moyamoya vessels) in the vicinity of the stenotic areas were noted (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nijasri Suwanwela, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29506=[""].join("\n");
var outline_f28_52_29506=null;
var title_f28_52_29507="Primary hyperparathyroidism";
var content_f28_52_29507=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Primary hyperparathyroidism (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/52/29507/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29507/contributors\" id=\"au4062\">",
"       Ghada El-Hajj Fuleihan, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/52/29507/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29507/contributors\" id=\"se178\">",
"       Clifford J Rosen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/52/29507/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29507/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/52/29507?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HYPERPARATHYROIDISM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Primary hyperparathyroidism is a disorder of one or more of the parathyroid glands (",
"     <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"      figure 1",
"     </a>",
"     ). The parathyroid gland(s) becomes overactive and secretes excess amounts of parathyroid hormone. As a result, the blood calcium rises to a level that is higher than normal (called hypercalcemia). An elevated calcium level can cause many short-term and long-term complications.",
"    </p>",
"    <p>",
"     Primary hyperparathyroidism is different from secondary hyperparathyroidism, which occurs when the parathyroid glands overproduce parathyroid hormone in response to low blood levels of calcium; the low calcium level is caused by another condition, such as not being absorbed correctly from the intestines or kidney failure.",
"    </p>",
"    <p>",
"     This topic discusses the causes, symptoms, diagnosis, and treatment of primary hyperparathyroidism. Secondary hyperparathyroidism is discussed separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"      \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS THE PARATHYROID GLAND?",
"     </span>",
"    </p>",
"    <p>",
"     Four parathyroid glands are located in the neck, two on each side (",
"     <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"      figure 1",
"     </a>",
"     ). Rarely, a person has five or six parathyroid glands in the neck, and occasionally one or more parathyroid glands located within the chest cavity. These small glands secrete a hormone called parathyroid hormone (or PTH) that helps the body maintain a normal blood calcium level.",
"    </p>",
"    <p>",
"     When the blood calcium level drops, the normal response is for the parathyroid glands to release PTH to raise the blood calcium level back to normal. The blood calcium level is normally maintained by the kidneys, bones, and indirectly by the intestines. When the blood calcium level rises, less PTH is released by the parathyroid glands, causing the kidneys to retain less calcium. These actions help keep the body's calcium level within a normal range.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HYPERPARATHYROIDISM CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Hyperparathyroidism can be caused by several conditions, including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A non-cancerous tumor (an adenoma) in one of the parathyroid glands; this is the most common cause.",
"      </li>",
"      <li>",
"       Enlargement of one or more of the parathyroid glands due to an overgrowth of normal cells, called hyperplasia.",
"      </li>",
"      <li>",
"       Parathyroid cancer; this is rare and accounts for less than 1 percent of all cases.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Hyperparathyroidism can occur at any age, but is more common in older postmenopausal women. At young ages, hyperparathyroidism is often caused by a familial hyperparathyroidism syndrome, which usually causes several of the parathyroid gland to enlarge rather than a single gland to become enlarged. In familial hyperparathyroidism, there is also a possibility of abnormalities of other endocrine glands, including the pituitary, thyroid, pancreas, or adrenal glands.",
"    </p>",
"    <p>",
"     Hyperparathyroidism has been reported in patients with a history of irradiation to the head and neck (eg, for the treatment of childhood malignancy, for the treatment of benign conditions, or after nuclear power plant accidents). The clinical presentation of radiation-related hyperparathyroidism is usually similar to that of hyperparathyroidism that is not related to radiation exposure. However, radiation exposed patients have more concurrent thyroid tumors.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HYPERPARATHYROIDISM SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     About 80 percent of people with hyperparathyroidism have few or no symptoms. In these people, hyperparathyroidism is typically detected when a blood test is done for some other reason. Most often, the calcium level is only mildly elevated or is elevated intermittently. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"      \"Clinical manifestations of primary hyperparathyroidism\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, there are sometimes non-specific symptoms that might be related to the elevated calcium level, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Joint aches",
"      </li>",
"      <li>",
"       Fatigue",
"      </li>",
"      <li>",
"       Weakness",
"      </li>",
"      <li>",
"       Loss of appetite",
"      </li>",
"      <li>",
"       Mild depression",
"      </li>",
"      <li>",
"       Difficulty concentrating",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Symptoms become more noticeable as the PTH and blood calcium levels rise. At higher levels of PTH and blood calcium, there may be a significant loss of appetite, nausea, constipation, excessive thirst, or frequent urination. In addition, a person may develop:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Impaired kidney function &mdash; The elevated calcium level can affect the kidney's ability to filter blood.",
"      </li>",
"      <li>",
"       Kidney stones &mdash; As calcium levels rise, the kidneys excrete more calcium into the urine, which can cause kidney stones to develop. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"        \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Bone disease &mdash; As calcium is reabsorbed from bone, bone density may decrease. As a result, the risk of bone fractures may increase in some patients.",
"      </li>",
"      <li>",
"       Rheumatologic symptoms &mdash; Gout or hardening (calcification) of cartilage in the wrists or knees can sometimes occur. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"        \"Patient information: Gout (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Imbalances in other chemicals &mdash; Some people develop a decreased blood phosphate level and a slightly increased magnesium level.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Parathyroid crisis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parathyroid crisis is a rare condition that sometimes occurs when people with hyperparathyroidism experience another illness, like vomiting or diarrhea, which causes excessive fluid loss or severely limits the amount of fluid they can consume.",
"    </p>",
"    <p>",
"     During parathyroid crisis, blood PTH and calcium levels rise sharply, causing severe symptoms of hypercalcemia. Most notably, there is a significant change in thinking and alertness, ranging from confusion to coma. Some people also experience severe abdominal pain, nausea, vomiting, stomach ulcers, and pancreatitis (inflammation of the pancreas).",
"    </p>",
"    <p>",
"     Parathyroid crisis must be treated quickly by replacing lost body fluids and removing the overactive parathyroid tissue.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HYPERPARATHYROIDISM DIAGNOSIS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hyperparathyroidism is diagnosed based upon levels of blood calcium and parathyroid hormone. In most people with hyperparathyroidism, both levels are higher than normal. Occasionally, a person may have an elevated calcium level and a normal or minimally elevated PTH level. Since PTH should normally be low when calcium is elevated, a minimally elevated PTH is considered abnormal and indicates hyperparathyroidism. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"      \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Bone density testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bone density testing is usually recommended for people with hyperparathyroidism. This test can help determine if the bones have become weakened as a result of abnormal blood calcium levels. Dual x-ray absorptiometry (DXA) testing is the most commonly used method for measuring bone density. This test is described in detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Kidney stone testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Testing for \"silent\" kidney stones is not recommended when you are first diagnosed with hyperparathyroidism. Testing is recommended, however, if you have had a kidney stone previously. Testing usually involves an ultrasound or CT scan of the kidneys. Further testing is not needed after the initial screening unless a person develops signs or symptoms of a stone. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      HYPERPARATHYROIDISM TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Non-surgical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Non-surgical treatment may be recommended for people who have no symptoms and whose blood calcium is only mildly elevated. Blood calcium levels should be measured every six months, and tests of kidney function are recommended once per year. Bone density testing is usually recommended every one to three years, depending upon your situation. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"      \"Management of primary hyperparathyroidism\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      General measures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with hyperparathyroidism who do not have symptoms are advised to:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid lithium (a mood stabilizer used for bipolar illness) and thiazide diuretics (used to treat high blood pressure) since these drugs may further increase blood calcium levels.",
"      </li>",
"      <li>",
"       Avoid excessive loss of body fluids (eg, dehydration), prolonged bed rest or inactivity, and a high calcium diet since these can increase blood calcium levels.",
"      </li>",
"      <li>",
"       Minimize bone loss by remaining active.",
"      </li>",
"      <li>",
"       Drink an adequate amount of fluid throughout the day. This may help to minimize the risk of kidney stones.",
"      </li>",
"      <li>",
"       Maintain a moderate calcium intake (about 1000",
"       <span class=\"nowrap\">",
"        mg/day)",
"       </span>",
"       (",
"       <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"        table 1",
"       </a>",
"       and",
"       <a class=\"graphic graphic_table graphicRef70454 \" href=\"UTD.htm?36/37/37468\">",
"        table 2",
"       </a>",
"       ). Lower calcium intake will stimulate more PTH secretion while higher calcium intake may worsen high calcium levels. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"        \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Consume a moderate amount of vitamin D (400 to 600 Int. Units daily) (",
"       <a class=\"graphic graphic_table graphicRef77982 \" href=\"UTD.htm?7/12/7372\">",
"        table 3",
"       </a>",
"       ). Vitamin D deficiency can stimulate PTH secretion and bone resorption and should be avoided. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"        \"Patient information: Vitamin D deficiency (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Treat bone loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications that inhibit bone resorption may be prescribed if you have evidence of decreased bone density (osteopenia or osteoporosis). These medications can protect the bones from the bone thinning effects of excess parathyroid hormone but will not normalize the calcium levels in the blood.",
"    </p>",
"    <p>",
"     A full discussion of treatments for osteoporosis is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Trials are currently ongoing to evaluate the safety and efficacy of drugs that decrease parathyroid hormone levels; this could reverse all the effects of hyperparathyroidism, including elevations in serum calcium levels.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Surgical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is often recommended for people with symptoms or whose blood calcium is moderately elevated. Surgery is also recommended for people with signs of impaired kidney function or decreased bone density. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H11#H11\">",
"      \"Management of primary hyperparathyroidism\", section on 'Candidates for surgery'",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is also recommended if the person is less than 50 years old or if periodic follow-up would be difficult (eg, if a person lived a great distance from a healthcare provider or travels to places where it is difficult to find medical care).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Traditional surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;The surgery is usually performed while the person is under anesthesia. An incision is made in the lower neck measuring 2.5 to 10 cm (1 to 5 inches). Usually, at least one abnormal-appearing gland is removed while the normal-appearing glands are left in place.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Minimally invasive surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several kinds of minimally invasive surgery can be performed in cases where one abnormal parathyroid gland has been located by a pre-operative imaging study.",
"    </p>",
"    <p>",
"     The surgery can be performed under local nerve block, and is a good alternative for patients who are at high-risk for general anesthesia. During the surgery, a small incision (1 to 4 cm or 0.4 to 1.8 inches) is made in the neck and the abnormal tissue is removed. The patient's blood level of PTH is tested before and immediately after removal to confirm that the PTH level drops significantly after the abnormal tissue is removed.",
"    </p>",
"    <p>",
"     The advantage of minimally invasive surgery compared with traditional surgery is that it requires a smaller incision, less time under anesthesia, and a shorter hospital stay. This type of procedure is only available for people with certain characteristics and it requires an experienced surgeon and medical center. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"      \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466887#H10466887\">",
"      \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Intraoperative parathyroid hormone monitoring'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Effectiveness of surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;With an experienced endocrine surgeon, surgical treatment is effective in curing hyperparathyroidism in about 95 percent of patients. The complication rate associated with surgery is very low.",
"    </p>",
"    <p>",
"     Complications could include temporary or permanent damage to the other parathyroid glands resulting in low calcium levels, bleeding,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     temporary or permanent hoarseness. Patients are hospitalized for a short time after surgery, usually for less than two days.",
"    </p>",
"    <p>",
"     Occasionally, some abnormal parathyroid tissue goes undetected and is not removed during the first operation. In this case, high calcium levels and symptoms of hyperparathyroidism persist after surgery. Imaging studies are required to locate the abnormal parathyroid tissue. In some patients, parathyroid glands may be present in unusual locations, such as in the chest or in other regions of the neck. A second surgical procedure is usually required to remove remaining abnormal tissue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Follow up care after surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Six to eight weeks after surgery, most clinicians recommend a blood test to measure the blood level of calcium and PTH. These tests are then repeated once per year to ensure that they remain normal and that abnormal tissue has not regrown. A bone density test may be recommended one year after surgery to guide treatment of bone loss (osteopenia or osteoporosis) (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Bone density testing'",
"     </a>",
"     above).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804424994\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H491875\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=see_link\">",
"      Patient information: Primary hyperparathyroidism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H491883\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/62/15331?source=see_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institutes of Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://endocrine.niddk.nih.gov/pubs/hyper/index.aspx\">",
"      endocrine.niddk.nih.gov/pubs/hyper/index.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org\">",
"      www.hormone.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/52/29507/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/52/29507?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29507/abstract/1\">",
"      Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29507/abstract/2\">",
"      Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002; 17 Suppl 2:N2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29507/abstract/3\">",
"      Chan AK, Duh QY, Katz MH, et al. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg 1995; 222:402.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_52_29507=[""].join("\n");
var outline_f28_52_29507=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HYPERPARATHYROIDISM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS THE PARATHYROID GLAND?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HYPERPARATHYROIDISM CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HYPERPARATHYROIDISM SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HYPERPARATHYROIDISM DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           HYPERPARATHYROIDISM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\" title=\"figure 1\">",
"           Thyroid anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\" title=\"table 1\">",
"           Foods with calcium PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?36/37/37468\" title=\"table 2\">",
"           Calcium supplements PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?7/12/7372\" title=\"table 3\">",
"           Sources of vitamin D PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_52_29508="Fluorouracil (topical): Pediatric drug information";
var content_f28_52_29508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorouracil (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/58/13221?source=see_link\">",
"    see \"Fluorouracil (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=see_link\">",
"    see \"Fluorouracil (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8100790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carac&reg;;",
"     </li>",
"     <li>",
"      Efudex&reg;;",
"     </li>",
"     <li>",
"      Fluoroplex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8100791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Efudex&reg;;",
"     </li>",
"     <li>",
"      Fluoroplex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10492987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10493066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/58/13221?source=see_link\">",
"      see \"Fluorouracil (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Actinic keratoses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Efudex&reg; or Fluoroplex&reg;: Apply twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Carac&trade;: Apply once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Basal cell carcinoma: Efudex&reg;: Apply twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 5% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carac&reg;: 0.5% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Efudex&reg;: 5% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoroplex&reg;: 1% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 2% (10 mL); 5% (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Efudex&reg;: 5% (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8100815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10493084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Not for ophthalmic or intravaginal use. Cleanse affected area thoroughly and wait 10 minutes before applying. Apply with a nonmetallic applicator or gloved fingers in a sufficient amount to cover affected area. Avoid contact with eyes, eyelids, nostrils, and mouth. Do not cover area with an occlusive dressing. Wash hands after application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% or 2%: Apply to lesions on the head and neck for the treatment of multiple actinic keratoses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5%: Use on lesions in areas other than the head and neck for multiple actinic keratoses; only 5% preparations are used for the treatment of superficial basal cell carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10493045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10492990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of multiple actinic or solar keratoses and superficial basal cell carcinomas (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8100787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fluorouracil may be confused with flucytosine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8100848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Systemic toxicity normally associated with parenteral administration (including neutropenia, neurotoxicity, and gastrointestinal toxicity) has been associated with topical use particularly in patients with a genetic deficiency of dihydropyrimidine dehydrogenase (DPD).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, insomnia, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, photosensitivity, pruritus, rash, scarring, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal:  Medicinal taste, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reactions: Allergic contact dermatitis, burning, crusting, dryness, edema, erosion, erythema, hyperpigmentation, irritation, pain, soreness, ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Eye irritation (burning, watering, sensitivity, stinging, itching)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Birth defects, herpes simplex, miscarriage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10492991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorouracil or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10492992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration to patients with genetic dihydropyrimidine dehydrogenase (DPD) enzyme deficiency has been associated with increased toxicity following administration (diarrhea, stomatitis, neutropenia, and neurotoxicity). Absence of the DPD enzyme may result in prolonged fluorouracil clearance. Systemic toxicity normally associated with parenteral administration has also been associated with topical use, particularly in patients with DPD enzyme deficiency; discontinue if symptoms of DPD enzyme deficiency occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid topical application to mucous membranes due to potential for local inflammation and ulceration. The use of occlusive dressings with topical preparations may increase the severity of inflammation in nearby skin areas. Avoid exposure to ultraviolet rays during and immediately following therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9844111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8100864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Fluorouracil (Topical) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemcitabine: May increase the serum concentration of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Fluorouracil (Topical) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May decrease the serum concentration of Fluorouracil (Topical). SORAfenib may increase the serum concentration of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fluorouracil (Topical) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8100839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8100840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed with parenteral administration in animal studies; fetal defects and miscarriages have been reported following use of topical products in humans. Use is contraindicated during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10493046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pyrimidine antimetabolite that inhibits thymidylate synthase leading to depletion of the DNA precursor thymidine; incorporated into RNA, DNA",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10493085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=see_link\">",
"      see \"Fluorouracil (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report signs and symptoms of infection, bleeding, bruising, vision changes, unremitting nausea, vomiting, or diarrhea, chest pain or palpitations, or CNS changes. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Women of childbearing age should be advised to avoid becoming pregnant.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15989 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.96.59.103-A977B79397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29508=[""].join("\n");
var outline_f28_52_29508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100790\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492987\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493066\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100940\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100815\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493084\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493045\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492990\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100787\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100848\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492991\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492992\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844111\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100864\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100839\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100840\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493046\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10493085\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10921?source=related_link\">",
"      Fluorouracil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/24/11653?source=related_link\">",
"      Fluorouracil (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/10/1190?source=related_link\">",
"      Fluorouracil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/58/13221?source=related_link\">",
"      Fluorouracil (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=related_link\">",
"      Fluorouracil (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_52_29509="Third degree or complete AV block with wide QRS escape";
var content_f28_52_29509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Third degree (complete) atrioventricular block with wide QRS escape rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 68px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The P waves are completely dissociated from the QRS complexes and the PR intervals are variable. The atrial or PP rate (75 beats per minute) is faster than the ventricular or RR rate (30 beats per minute), establishing complete atrioventricular nodal blockade as the etiology. The QRS complexes are wide indicating that the escape rhythm is ventricular.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29509=[""].join("\n");
var outline_f28_52_29509=null;
var title_f28_52_29510="Lidocaine and epinephrine: Drug information";
var content_f28_52_29510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine and epinephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/23/9588?source=see_link\">",
"    see \"Lidocaine and epinephrine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38084?source=see_link\">",
"    see \"Lidocaine and epinephrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lignospan&reg; Forte;",
"     </li>",
"     <li>",
"      Lignospan&reg; Standard;",
"     </li>",
"     <li>",
"      Xylocaine&reg; MPF With Epinephrine;",
"     </li>",
"     <li>",
"      Xylocaine&reg; With Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xylocaine&reg; With Epinephrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage varies with the anesthetic procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dental anesthesia, infiltration, or conduction block:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years: 20-30 mg (1-1.5 mL) of lidocaine hydrochloride as a 2% solution with epinephrine 1:100,000; maximum: 4.5 mg of lidocaine hydrochloride/kg of body weight or 100-150 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: Do not exceed 7 mg/kg body weight up to a maximum range of 300 mg (usual dental practice) to 500 mg (approved product labeling) of lidocaine hydrochloride and 3 mcg (0.003 mg) of epinephrine/kg of body weight or 0.2 mg epinephrine per dental appointment. The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required, and physical condition of the patient. Always use the lowest effective dose along with careful aspiration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For most routine dental procedures, lidocaine hydrochloride 2% with epinephrine 1:100,000 is preferred. When a more pronounced hemostasis is required, a 1:50,000 epinephrine concentration should be used.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F188661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38084?source=see_link\">",
"      see \"Lidocaine and epinephrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage varies with the anesthetic procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dental anesthesia, infiltration, or conduction block:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years: 20-30 mg (1-1.5 mL) of lidocaine hydrochloride as a 2% solution with epinephrine 1:100,000; maximum: 4.5 mg of lidocaine hydrochloride/kg of body weight or 100-150 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For most routine dental procedures, lidocaine hydrochloride 2% with epinephrine 1:100,000 is preferred. When a more pronounced hemostasis is required, a 1:50,000 epinephrine concentration should be used.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, accumulation of metabolites may be increased in renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection, solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     0.5% / 1:200,000: Lidocaine hydrochloride 0.5% [5 mg/mL] and epinephrine 1:200,000 (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1% / 1:100,000: Lidocaine hydrochloride 1% [10 mg/mL] and epinephrine 1:100,000 (20 mL, 30 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:100,000:  Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (30 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Xylocaine&reg; with Epinephrine:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.5% / 1:200,000: Lidocaine hydrochloride 0.5% [5 mg/mL] and epinephrine 1:200,000 (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1% / 1:100,000: Lidocaine hydrochloride 1% [10 mg/mL] and epinephrine 1:100,000 (10 mL, 20 mL, 50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (10 mL, 20 mL, 50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection, solution",
"     </b>",
"     [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1.5% / 1:200,000: Lidocaine hydrochloride 1.5% [15 mg/mL] and epinephrine 1:200,000 (5 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:200,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:200,000 (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Xylocaine&reg;-MPF with Epinephrine:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1% / 1:200,000: Lidocaine hydrochloride 1% [10 mg/mL] and epinephrine 1:200,000 (5 mL, 10 mL, 30 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1.5% / 1:200,000: Lidocaine hydrochloride 1.5% [15 mg/mL] and epinephrine 1:200,000 (5 mL, 10 mL, 30 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:200,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:200,000 (5 mL, 10 mL, 20 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection, solution",
"     </b>",
"     [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:50,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:50,000 (1.7 mL, 1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (1.7 mL, 1.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lignospan&reg; Forte: 2% / 1:50,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:50,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Lignospan&reg; Standard: 2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains edetate disodium, potassium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Xylocaine&reg; Dental with Epinephrine:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:50,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:50,000 (1.7 mL; 1.8 mL [DSC]) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2% / 1:100,000: Lidocaine hydrochloride 2% [20 mg/mL] and epinephrine 1:100,000 (1.7 mL; 1.8 mL [DSC]) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F188637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Injection solution for infiltration: Before injecting, withdraw syringe plunger to ensure injection is not into vein or artery. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local infiltration anesthesia; AVS for nerve block",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F188666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Degree of adverse effects in the central nervous system and cardiovascular system are directly related to the blood levels of lidocaine. The effects below are more likely to occur after systemic administration rather than infiltration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Myocardial effects include a decrease in contraction force as well as a decrease in electrical excitability and myocardial conduction rate resulting in bradycardia and reduction in cardiac output.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: High blood levels result in anxiety, restlessness, disorientation, confusion, dizziness, tremor, and seizure. This is followed by depression of CNS resulting in somnolence, unconsciousness and possible respiratory arrest. In some cases, symptoms of CNS stimulation may be absent and the primary CNS effects are somnolence and unconsciousness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypersensitivity reactions: Extremely rare, but may be manifest as dermatologic reactions and edema at injection site. Asthmatic syndromes have occurred. Patients may exhibit hypersensitivity to bisulfites contained in local anesthetic solution to prevent oxidation of epinephrine. In general, patients reacting to bisulfites have a history of asthma and their airways are hyper-reactive to asthmatic syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Psychogenic reactions: It is common to misinterpret psychogenic responses to local anesthetic injection as an allergic reaction. Intraoral injections are perceived by many patients as a stressful procedure in dentistry. Common symptoms to this stress are diaphoresis, palpitation, hyperventilation, generalized pallor and a fainting feeling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F188640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lidocaine, epinephrine, or any component of the formulation; hypersensitivity to other local anesthetics of the amide type; myasthenia gravis; shock; cardiac conduction disease; angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F188624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is",
"     <b>",
"      not",
"     </b>",
"     an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use minimal amounts in patients with significant cardiovascular problems (because of epinephrine component).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disease: Use with caution in patients with endocrine disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease; avoid in patients with uncontrolled hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flammable anesthetics: Avoid use in presence of flammable anesthetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Aspirate the syringe (injection solution for infiltration formulation) after tissue penetration and before injection to minimize chance of direct vascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: May contain sodium metabisulfite; use caution in patients with a sulfite allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners and/or clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F188662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lidocaine enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F188644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Lidocaine(Systemic) and Epinephrine (Systemic) monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lidocaine-Epinephrine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2%-1:200000 (20 mL): $9.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xylocaine-MPF/Epinephrine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1:200000% (30 mL): $13.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-1:200000% (30 mL): $15.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1:200000% (20 mL): $15.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xylocaine/Epinephrine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-1:200000% (50 mL): $7.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1:100000% (10 mL): $2.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1:100000% (20 mL): $4.56",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F188623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lidocaine blocks both the initiation and conduction of nerve impulses via decreased permeability of sodium ions; epinephrine increases the duration of action of lidocaine by causing vasoconstriction (via alpha effects) which slows the vascular absorption of lidocaine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F188639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: ~5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~2 hours; dose and anesthetic procedure dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gaffen AS and Haas DA, \"Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry,\"",
"      <i>",
"       J Can Dent Assoc",
"      </i>",
"      , 2009, 75(8):579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/19840499/pubmed\" id=\"19840499\" target=\"_blank\">",
"        19840499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garisto GA, Gaffen AS, Lawrence HP, et al, \"Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2010, 141(7):836-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/20592403/pubmed\" id=\"20592403\" target=\"_blank\">",
"        20592403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacKenzie TA and Young ER, &ldquo;Local Anesthetic Update,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1993, 40(2):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/8185087/pubmed\" id=\"8185087\" target=\"_blank\">",
"        8185087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(1):16, 18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/7911769/pubmed\" id=\"7911769\" target=\"_blank\">",
"        7911769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Recent Research on Mechanisms of Local Anesthetics,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1995, 43(4):316-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/8940589/pubmed\" id=\"8940589\" target=\"_blank\">",
"        8940589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yagiela JA, &ldquo;Injectable and Topical Local Anesthetics,\"",
"      <i>",
"       ADA Guide to Dental Therapeutics",
"      </i>",
"      , 2nd ed, Ciancio SG, ed, Chicago IL: ADA Publishing, 2000, 3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/1819966/pubmed\" id=\"1819966\" target=\"_blank\">",
"        1819966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yagiela JA, &ldquo;Local Anesthetics,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1991, 38(4-5):128-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/52/29510/abstract-text/1819966/pubmed\" id=\"1819966\" target=\"_blank\">",
"        1819966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9559 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29510=[""].join("\n");
var outline_f28_52_29510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188651\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188652\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188668\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188654\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188661\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188655\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265600\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265601\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188634\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188620\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188637\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188636\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188666\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188640\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188624\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188662\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188629\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188631\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188643\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188657\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188644\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323312\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188623\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188639\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9559|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/23/9588?source=related_link\">",
"      Lidocaine and epinephrine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38084?source=related_link\">",
"      Lidocaine and epinephrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_52_29511="Approach to the patient with neutrophilia";
var content_f28_52_29511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with neutrophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29511/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29511/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29511/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29511/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29511/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29511/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/52/29511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal total white blood cell (WBC) count in adults varies from 4400 to 11,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (4.4 to 11.0 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L),",
"    </span>",
"    the majority of which (approximately 60 percent) are mature neutrophils. Leukocytosis is defined as a total WBC more than two standard deviations above the mean, or a value of greater than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    in adults. By convention, leukocytosis to values in excess of 50,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    when due to causes other than leukemia, is termed a leukemoid reaction or hyperleukocytosis.",
"   </p>",
"   <p>",
"    While leukocytosis is most commonly due to an increase in the absolute number of mature neutrophils (neutrophilia), it can also reflect a marked increase in the absolute numbers of lymphocytes, eosinophils, monocytes, or, more rarely, basophils. Granulocytosis is generally used interchangeably with neutrophilia, although the two terms are somewhat different, since granulocytosis can also reflect leukocytosis due to increased numbers of eosinophils or basophils.",
"   </p>",
"   <p>",
"    Neutrophilic leukocytosis is defined as a total WBC greater than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    plus an absolute neutrophil count (ANC) more than two standard deviations above the mean, or a value greater than",
"    <span class=\"nowrap\">",
"     7700/microL",
"    </span>",
"    in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31303?source=see_link\">",
"     \"Definition and mechanisms of leukocytosis and neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ANC is equal to the product of the white blood cell count (WBC) and the percentage of polymorphonuclear cells (PMNs) and band forms noted on the WBC differential, and is calculated as follows:",
"   </p>",
"   <p>",
"    ANC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    &nbsp;= &nbsp;WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    &nbsp;x &nbsp;percent (PMNs &nbsp;+ &nbsp;bands) &nbsp;&divide; &nbsp;100",
"   </p>",
"   <p>",
"    An ANC above",
"    <span class=\"nowrap\">",
"     7700/microL",
"    </span>",
"    in patient with a total WBC less than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    is called neutrophilia. An example of a setting in which this might occur is the patient with AIDS in whom an increase in neutrophils may be offset by the presence of significant lymphopenia. However, for the purposes of this discussion, neutrophilia will be synonymous with neutrophilic leukocytosis.",
"   </p>",
"   <p>",
"    This topic review will present a clinical approach to the patient with neutrophilia. The causes of this disorder are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"UTD.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link\">",
"     \"Causes of neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is true for the approach to any medical problem, there is no substitute for an accurate history and physical examination. However, before this process is started, the clinician must make sure that there is no laboratory error involved. Specifically, blood counts that do not make sense within the context of the clinical findings should be repeated before extensive evaluation is undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain conditions associated with neutrophilia are obvious and should be immediately recognized by the clinician (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"UTD.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=see_link\">",
"     \"Causes of neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any active inflammatory condition or infection",
"     </li>",
"     <li>",
"      Cigarette smoking, which may be the most common cause of mild neutrophilia",
"     </li>",
"     <li>",
"      Pregnancy and following uncomplicated spontaneous or cesarean delivery",
"     </li>",
"     <li>",
"      Previously diagnosed hematologic disease (such as acute and chronic leukemias, chronic myeloproliferative or myelodysplastic disease)",
"     </li>",
"     <li>",
"      The presence of, and treatment for, a chronic anxiety state, panic disorder, rage, or emotional stress (eg, posttraumatic stress disorder, depression)",
"     </li>",
"     <li>",
"      Recent vigorous exercise",
"     </li>",
"     <li>",
"      Recent thermal burn, electric shock, surgery, or trauma",
"     </li>",
"     <li>",
"      Presence of non-hematologic diseases known to increase neutrophil counts (eg, eclampsia, thyroid storm, hypercortisolism).",
"     </li>",
"     <li>",
"      Prior splenectomy or known asplenia",
"     </li>",
"     <li>",
"      Positive family history of neutrophilia",
"     </li>",
"     <li>",
"      Post-antibiotic diarrhea (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Medications'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Recent vaccination or snake bite",
"     </li>",
"     <li>",
"      Sickle cell disease, in which disorder leukocytosis within the first two years of life, in the absence of infection, predicts for increased disease severity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various medications may cause neutrophilia. However, with the exception of the drugs listed in the table (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"UTD.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ), such cases are rare and appear in the literature as isolated case reports. Nevertheless, it is good practice to search for such adverse effects through the pharmacy literature, especially when the patient is taking a medication whose side effects may not be widely known, or when the timing of onset of neutrophilia coincides with the institution of the medication.",
"   </p>",
"   <p>",
"    Unexplained leukocytosis in hospitalized patients, even without diarrhea, may represent a harbinger of C. difficile infection, which usually occur after 5 to 10 days of antibiotic treatment. Thus, testing for C. difficile infection may be reasonable in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H2#H2\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H15#H15\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     The physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important function of the physical examination, as regards the presence of neutrophilia, is to determine the presence or absence of infection, inflammation, or malignancy. Clues to the presence of such disorders include, but are not limited to, the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Hypotension, shock, tachycardia, hypothermia (eg, overwhelming sepsis)",
"     </li>",
"     <li>",
"      Abscess or evidence of infection at any site",
"     </li>",
"     <li>",
"      Abdominal rebound tenderness",
"     </li>",
"     <li>",
"      Signs of pulmonary consolidation or pleural effusion",
"     </li>",
"     <li>",
"      Joint swelling, erythema, tenderness",
"     </li>",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Lymphadenopathy",
"     </li>",
"     <li>",
"      Diarrhea (eg, C. difficile infection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings such as the above indicate the presence of significant disease, and require appropriate diagnostic workup, consultation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hospitalization of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INITIAL LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;This discussion presupposes that the patient is known to have an increased ANC as usually determined by an automated cell counter. The evaluation of this abnormal laboratory finding should begin with consideration of normal variation and spurious leukocytosis. Measurement of the sedimentation rate (ESR) and C-reactive protein (CRP), both of which are elevated in inflammation and infection, can be very helpful, particularly in an asymptomatic patient with leukocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Normal variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors contribute to the wide variability in neutrophil counts in normal populations. Particularly in the asymptomatic patient with persistent mild neutrophilia, one must remember that, by definition, the WBC count in 2.5 percent of the normal population will be greater than two standard deviations above the mean (ie,",
"    <span class=\"nowrap\">",
"     &gt;11,000/microL).",
"    </span>",
"    Since regulation of granulocyte production is in part genetically controlled, examination of the parents' or siblings' blood counts may be of help in these situations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one report described 34 otherwise healthy subjects with total leukocyte counts of 11,000 to",
"    <span class=\"nowrap\">",
"     40,000/microL,",
"    </span>",
"    with the remainder of their blood counts being normal, other than occasional thrombocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/2\">",
"     2",
"    </a>",
"    ]. Bone marrow aspirations and leukocyte alkaline phosphatase scores were normal. The subjects were followed for more than 20 years with no apparent medical problems becoming evident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spurious leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artifacts which spuriously raise the observed WBC can be seen due to blood sampling problems or in certain primary disease states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Platelet clumping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clumping of platelets, leading to artifactually high white blood cell counts, can occur under the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If anticoagulation of the sample is inadequate, the resulting platelet clumps can be counted as leukocytes by some automated cell counters. As a result, the WBC count is rarely increased by more than 10 percent and there is usually an associated spurious thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 0.1 percent of normal subjects have EDTA-dependent agglutinins which can lead to platelet clumping and spurious leukocytosis (also called pseudoleukocytosis) (",
"      <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"       picture 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An examination of the peripheral smear which shows platelet clumping is consistent with the presence of one of these artifacts. A repeat blood sample adequately anticoagulated with citrate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (rather than EDTA) should help resolve this problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cryoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cold-insoluble plasma proteins are present, a temperature-dependent increase in leukocyte and platelet counts occurs at temperatures of 30&ordm;C or less. This can result in WBC counts as high as",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and a doubling of the platelet count, both of which are attributed to various sizes of precipitated cryoglobulin particles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/6\">",
"     6",
"    </a>",
"    ]. This effect is increased if the sample is allowed to cool to lower temperatures and disappears if the sample is kept at body temperature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE COMPLETE BLOOD COUNT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of neutrophilia requires that the patient has had (at least) a total WBC count and a WBC differential performed, either manually or via an automated cell counter. Thus, the clinician almost always has additional information at hand with which to evaluate the finding of neutrophilia. This will depend upon the methodology used, although most blood counts are now performed using automated cell counters, all of which employ computer programs for \"flagging\" abnormalities (eg, multipart differential counts, presence of immature cells and blasts, left shift indicators, cells with increased peroxidase activity, lobularity index, and the presence of nucleated red blood cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link\">",
"     \"Automated hematology instrumentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, automated differential WBC counts will be superior to 100 cell manual differential counts, since the former can sample and evaluate up to 10,000 nucleated cells, with resulting increases in precision. As an example, in a patient with a WBC of",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    and 60 percent neutrophils, the coefficient of variation for the ANC will be 13 and 1.3 percent for a 100 and 10,000 cell differential, respectively. However, small numbers of immature cells of the neutrophil series and the presence of a \"left shift\" (usually defined as a band form count greater than",
"    <span class=\"nowrap\">",
"     700/microL)",
"    </span>",
"    may be missed with all methods. A well prepared blood smear examined by a trained clinician or laboratorian can add significant information under such circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Detection of infection or inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of other parameters on the blood count for diagnosing the presence of infectious or inflammatory disease (ID) was studied in 292 patients, using an elevated level of C-reactive protein (CRP) as the gold standard for the presence of ID [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/8\">",
"     8",
"    </a>",
"    ]. Study parameters included a manual 200 cell differential count of neutrophil band forms, machine-derived WBC and neutrophil counts, and the \"left shift\" parameters from two different automated counters. The results indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The highest specificity for the presence of ID (79 percent) was found for a manual band count &ge;20 percent of the total WBC and the left shift flag from the Technicon H-1 analyzer.",
"     </li>",
"     <li>",
"      The highest sensitivity for the presence of ID (80 percent) was the presence of Dohle bodies, toxic granulation, and cytoplasmic vacuoles from manual examination of the peripheral smear (",
"      <a class=\"graphic graphic_picture graphicRef70248 \" href=\"UTD.htm?7/17/7449\">",
"       picture 2",
"      </a>",
"      ) and the left-shift indicator of the Coulter MAX M analyzer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second study, employing results from preoperative blood counts in 40 patients with a clinical diagnosis of acute appendicitis, 33 of whom showed acute inflammation histologically, also indicated a sensitivity of 79 percent for the Technicon H-1 analyzer's left shift flag [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the highest sensitivity (91 percent) for predicting the presence of acute inflammation was a total WBC count above",
"    <span class=\"nowrap\">",
"     10,500/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Similar findings were noted in a blinded preoperative study of 204 patients with suspected acute appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/10\">",
"     10",
"    </a>",
"    ]. The highest sensitivity (83 percent) for predicting the presence of acute appendicitis was the total WBC count. The sensitivity of testing could be increased to 100 percent by employing an elevated WBC or an elevated CRP or an increased neutrophil percentage as a single parameter. However, this lowered specificity and decreased the positive predictive value to 37 percent. The same triple test combination had a negative predictive value of 100 percent, indicating that appendicitis is unlikely when all three tests are simultaneously negative (normal).",
"   </p>",
"   <p>",
"    Evaluation of the ESR and CRP are particularly helpful in detecting occult inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29139673\">",
"    <span class=\"h2\">",
"     Complete blood counts in family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial leukocytosis has been reported, as has chronic idiopathic leukocytosis. (See",
"    <a class=\"local\" href=\"#H9379034\">",
"     'Causes of leukocytosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Combined abnormalities on the complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following additional findings on the differential count and the CBC can be of importance in evaluation of the neutrophilic patient:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of anemia and neutrophilia is a nonspecific finding, and can be seen in many different settings, such as chronic infection or inflammation, hemolytic anemia, and malignancies. Clues to the diagnosis may be available on examination of the peripheral smear or evaluation of the red blood cell (RBC) indices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Increased hematocrit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of neutrophilia and polycythemia suggests the presence of polycythemia vera. Associated findings on the complete blood count, such as microcytic RBC indices, thrombocytosis, basophilia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eosinophilia, and small numbers of immature cells of the granulocyte series are often seen (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"UTD.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Increased platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of neutrophilia and an elevated platelet count does not necessarily add significant information, since both elements can be increased in infectious, inflammatory, or malignant conditions, or following periods of marrow recovery (see below). However, this combination in an asymptomatic patient may suggest the presence of essential thrombocythemia (primary thrombocytosis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link\">",
"     \"Approach to the patient with thrombocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Decreased platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of neutrophilia and thrombocytopenia is most frequently seen in sepsis due to acute bacterial infection, with or without disseminated intravascular coagulation. Associated findings on the peripheral smear are a pronounced left shift plus changes in the neutrophils, such as toxic granulations, Dohle bodies, and cytoplasmic vacuoles (",
"    <a class=\"graphic graphic_picture graphicRef70248 \" href=\"UTD.htm?7/17/7449\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An important and potentially fatal but treatable condition which can present with this combination is thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS). Associated findings on the CBC and peripheral smear are the presence of microangiopathic RBC changes (ie, hemolytic anemia, fragmented RBCs, reticulocytosis), and the presence of enlarged platelets (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 3",
"    </a>",
"    ). The WBC is elevated in about 50 percent of patients with TTP-HUS, occasionally to levels above",
"    <span class=\"nowrap\">",
"     20,000/microL;",
"    </span>",
"    neutrophilia may be associated with a poor outcome in children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combined presence of thrombocytopenia and microangiopathic hemolytic anemia without another clinically apparent etiology are sufficient to suspect the diagnosis of TTP-HUS and initiate urgent hematologic consultation and plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nucleated RBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of neutrophilia and nucleated red blood cells in a patient without a primary hematologic disorder can be an ominous sign. It is seen most often in septic shock.",
"   </p>",
"   <p>",
"    These two findings may also be associated with teardrop shaped RBCs and early granulocytes in the blood, the so-called leukoerythroblastic blood picture (",
"    <a class=\"graphic graphic_picture graphicRef68110 graphicRef55274 \" href=\"UTD.htm?18/50/19242\">",
"     picture 4A-B",
"    </a>",
"    ). This combination suggests the presence of infiltrative marrow disease (eg, myelofibrosis, malignancy, granulomatous disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Left shift in the WBC differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard definition of a left shift is a band form count greater than",
"    <span class=\"nowrap\">",
"     700/microL,",
"    </span>",
"    a condition often called \"bandemia.\" As an example, a band to total neutrophil count ratio greater than 0.16 is significantly associated with neonatal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/13\">",
"     13",
"    </a>",
"    ]. In infection, cells as immature as metamyelocytes are often seen on the peripheral smear, but it is unusual to see more immature cells (eg, myelocytes, promyelocytes, and blasts) in such a setting. When these latter cells are present, they indicate a \"severe left shift\", most likely due to the presence of an acute or chronic myeloproliferative disorder, such as chronic myeloid leukemia, idiopathic myelofibrosis, or one of the various forms of acute leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Monocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monocytes normally comprise less than 10 percent of total circulating white cells, with the absolute monocyte count being",
"    <span class=\"nowrap\">",
"     &lt;800/microL",
"    </span>",
"    in the normal adult.",
"   </p>",
"   <p>",
"    A number of conditions which cause neutrophilia can also cause monocytosis, making this combination a relatively nonspecific finding. These include pregnancy, the asplenic state, inflammatory (eg, sarcoidosis, inflammatory bowel disease) and autoimmune conditions, depression, and treatment with corticosteroids or colony stimulating factors. Monocytosis may also accompany conditions associated with neutropenia, presumably as a compensatory mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29511/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large number of infections have been associated with monocytosis including brucellosis, varicella-zoster, bacterial endocarditis, tuberculosis, malaria, typhoid fever, syphilis, and trypanosomiasis.",
"   </p>",
"   <p>",
"    Monocytosis may also be seen in certain malignancies, such as Hodgkin lymphoma. Neutrophilia with monocytosis may also suggest chronic myelomonocytic leukemia, one of the myelodysplastic disorders. Additional associated findings in this condition are anemia, thrombocytopenia and abnormal cellular maturation (eg, macrocytic red cells, defective lobulation in neutrophils, and abnormal size and granulation in platelets). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4009096#H4009096\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Bone marrow aspirate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monocytosis also may be seen in some forms of chronic myeloid leukemia as well as in the myelomonocytic and monoblastic variants of acute myeloid leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the bone marrow is of little help in evaluating the patient with neutrophilia, except in certain instances of leukemoid reactions, leukoerythroblastic blood picture (see above), or the presence of immature cells (ie, blasts and other cells more immature than the metamyelocyte) on the peripheral smear. Bone marrow biopsy should be included in these situations, as well as fungal and mycobacterial cultures. The biopsy may reveal granuloma, which may intensify the search for fungal infection or metastatic tumor that might be missed in a marrow aspirate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other ancillary tests may on occasion be of value in assessing the presence or absence of infection or inflammation, although a \"gold standard\" is not generally agreed upon. The most commonly employed tests for this purpose include serum C-reactive protein and the erythrocyte sedimentation rate. Other tests, which may not be generally available include plasma fibronectin concentration, neutrophil CD16 expression, and the percentage of cells of the neutrophil series with a high content of peroxidase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The leukocyte alkaline phosphatase (LAP) score, which is high in infection, inflammation, and polycythemia vera (PV) and low in chronic myeloid leukemia (CML) and paroxysmal nocturnal hemoglobinuria, may also be of help. It must be kept in mind, however, that the LAP score can be normal in PV and CML, particularly juvenile CML. Normal ranges for the LAP vary among laboratories; results may be unreliable in laboratories with minimal experience in performing the test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Existing radiotracer techniques to study neutrophil kinetics, although sophisticated, are not of much clinical use. Similarly, clinical tests such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) challenge or epinephrine stimulation, which reflect the presence of a releasable marrow storage pool or marginated pool, respectively, have limited differential diagnostic power and are not performed clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HYPERLEUKOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question arises concerning the level at which an extremely high WBC count (hyperleukocytosis, leukemoid reaction) can cause symptoms and warrant the consideration of",
"    <strong>",
"     emergency",
"    </strong>",
"    leukapheresis. Patients with neutrophil counts above",
"    <span class=\"nowrap\">",
"     250,000/microL",
"    </span>",
"    may require urgent hematologic consultation and intervention to prevent the vasoocclusive complications of hyperviscosity. In contrast, leukemic blast cells, because of their nondeformability, cause hyperviscosity at lower cell counts (approximately",
"    <span class=\"nowrap\">",
"     75,000/microL).",
"    </span>",
"    This is an unusual presenting problem because patients with rapidly evolving leukemia typically present with problems such as hemorrhage or thrombosis at considerably lower blast counts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9379019\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9379027\">",
"    <span class=\"h2\">",
"     Definitions and normal values",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal total white blood cell (WBC) count in adults varies from 4400 to 11,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      Leukocytosis is defined as a total WBC greater than",
"      <span class=\"nowrap\">",
"       11,000/microL",
"      </span>",
"      in adults.",
"     </li>",
"     <li>",
"      An absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;7700/microL",
"      </span>",
"      in patient with a total WBC less than",
"      <span class=\"nowrap\">",
"       11,000/microL",
"      </span>",
"      is called neutrophilia",
"     </li>",
"     <li>",
"      Leukocytosis to values in excess of 50,000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      when due to causes other than leukemia, is termed a leukemoid reaction or hyperleukocytosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Hyperleukocytosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9379034\">",
"    <span class=\"h2\">",
"     Causes of leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are major causes of leukocytosis (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"UTD.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ). Many will be obvious by history or physical examination. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Initial approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any active inflammatory condition or infection",
"     </li>",
"     <li>",
"      Cigarette smoking, which may be the most common cause of mild neutrophilia",
"     </li>",
"     <li>",
"      Pregnancy and following uncomplicated spontaneous or cesarean delivery",
"     </li>",
"     <li>",
"      Previously diagnosed hematologic disease",
"     </li>",
"     <li>",
"      Certain medications (eg, glucocorticoids, catecholamines)",
"     </li>",
"     <li>",
"      The presence of, and treatment for, a chronic anxiety state, panic disorder, rage, or emotional stress",
"     </li>",
"     <li>",
"      Recent vigorous exercise, thermal burn, electric shock, surgery, or trauma",
"     </li>",
"     <li>",
"      Laboratory artifact (eg, platelet clumping, cryoglobulinemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9379122\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient with leukocytosis should include a complete blood count, platelet count, WBC differential and examination of the peripheral blood smear as a minimum. Items to evaluate include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of a &ldquo;left shift&rdquo; in the WBC differential. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Left shift in the WBC differential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for",
"      <span class=\"nowrap\">",
"       infection/inflammation.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Detection of infection or inflammation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Other tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presence of anemia or polycythemia, thrombocytopenia or thrombocytosis,",
"      <span class=\"nowrap\">",
"       and/",
"      </span>",
"      or abnormal cells (eg, nucleated red cells, blasts, increased monocytes, atypical lymphocytes)",
"     </li>",
"     <li>",
"      Elevation of the erythrocyte sedimentation rate or C-reactive protein may indicate occult inflammatory disease.",
"     </li>",
"     <li>",
"      Examination of the bone marrow is of little help in evaluating the patient with neutrophilia, except in certain instances of leukemoid reactions, leukoerythroblastic blood picture, or the presence of immature cells (ie, blasts and other cells more immature than the metamyelocyte) on the peripheral smear.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/1\">",
"      Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/2\">",
"      Ward HN, Reinhard EH. Chronic idiopathic leukocytosis. Ann Intern Med 1971; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/3\">",
"      Caramihai E, Karayalcin G, Aballi AJ, Lanzkowsky P. Leukocyte count differences in healthy white and black children 1 to 5 years of age. J Pediatr 1975; 86:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/4\">",
"      Solanki DL, Blackburn BC. Spurious leukocytosis and thrombocytopenia. A dual phenomenon caused by clumping of platelets in vitro. JAMA 1983; 250:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/5\">",
"      Savage RA. Pseudoleukocytosis due to EDTA-induced platelet clumping. Am J Clin Pathol 1984; 81:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/6\">",
"      Patel KJ, Hughes CG, Parapia LA. Pseudoleucocytosis and pseudothrombocytosis due to cryoglobulinaemia. J Clin Pathol 1987; 40:120.",
"     </a>",
"    </li>",
"    <li>",
"     Morris MW, Williams WJ, Nelson DA. Automated blood cell counting. In: Williams' Hematology, 5th ed, Beutler E, Lichtman MA, Coller BS, Kipps TJ (Eds), McGraw-Hill, New York 1995. p.L3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/8\">",
"      Seebach JD, Morant R, R&uuml;egg R, et al. The diagnostic value of the neutrophil left shift in predicting inflammatory and infectious disease. Am J Clin Pathol 1997; 107:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/9\">",
"      Banez EI, Bacaling JH. An evaluation of the Technicon H-1 automated hematology analyzer in detecting peripheral blood changes in acute inflammation. Arch Pathol Lab Med 1988; 112:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/10\">",
"      Dueholm S, Bagi P, Bud M. Laboratory aid in the diagnosis of acute appendicitis. A blinded, prospective trial concerning diagnostic value of leukocyte count, neutrophil differential count, and C-reactive protein. Dis Colon Rectum 1989; 32:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/11\">",
"      Fitzpatrick MM, Shah V, Trompeter RS, et al. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int 1992; 42:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/12\">",
"      Robson WL, Fick GH, Wilson PC. Prognostic factors in typical postdiarrhea hemolytic-uremic syndrome. Child Nephrol Urol 1988; 9:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/13\">",
"      Christensen RD, Bradley PP, Rothstein G. The leukocyte left shift in clinical and experimental neonatal sepsis. J Pediatr 1981; 98:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29511/abstract/14\">",
"      Bellann&eacute;-Chantelot C, Clauin S, Leblanc T, et al. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood 2004; 103:4119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8381 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29511=[""].join("\n");
var outline_f28_52_29511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9379019\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      The physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INITIAL LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Normal variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spurious leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Platelet clumping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION OF THE COMPLETE BLOOD COUNT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Detection of infection or inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29139673\">",
"      Complete blood counts in family members",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Combined abnormalities on the complete blood count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Increased hematocrit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Increased platelet count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Decreased platelet count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nucleated RBC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Left shift in the WBC differential",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Monocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HYPERLEUKOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9379019\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9379027\">",
"      Definitions and normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9379034\">",
"      Causes of leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9379122\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8381|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26872\" title=\"picture 1\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/17/7449\" title=\"picture 2\">",
"      Toxic granulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 3\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 4A\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43606\" title=\"picture 4B\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/51/30524\" title=\"table 1\">",
"      Classification of neutrophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31303?source=related_link\">",
"      Definition and mechanisms of leukocytosis and neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_52_29512="Zenker's diverticulum";
var content_f28_52_29512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Zenker's diverticulum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29512/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29512/contributors\">",
"     Chris J J Mulder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29512/contributors\">",
"     Stijn J B van Weyenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29512/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29512/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/52/29512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zenker's diverticulum is an outpouching of the mucosa through Killian's triangle, an area of muscular weakness between the transverse fibers of the cricopharyngeus and the oblique fibers of the lower inferior constrictor. It is uncommon, with an annual incidence that has been estimated at 2 per 100,000 per year in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/1\">",
"     1",
"    </a>",
"    ]. The pharyngoesophageal diverticulum was first described by Ludlow in 1767 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/2\">",
"     2",
"    </a>",
"    ]. Zenker and von Ziemssen subsequently reviewed the world literature in 1877, and since then this kind of diverticulum has been called Zenker's diverticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Zenker's diverticulum is defined as a posterior diverticulum that has a neck proximal to the cricopharyngeal muscle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52971 \" href=\"UTD.htm?20/38/21102\">",
"     image 1",
"    </a>",
"    ). Most authors consider it among the other types of esophageal diverticula, all of which are outpouchings of one or more layers of the esophageal wall. \"True\" diverticula contain all layers of the intestinal wall. In contrast, \"false\" diverticula contain only mucosa and submucosa, while \"intramural\" diverticula are confined to the submucosa.",
"   </p>",
"   <p>",
"    The classification of esophageal diverticula depends upon their location. They predominantly occur in three areas:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediately above the upper esophageal sphincter (UES) (Zenker's diverticulum)",
"     </li>",
"     <li>",
"      Near the midpoint of the esophagus (traction diverticulum)",
"     </li>",
"     <li>",
"      Immediately above the lower esophageal sphincter (epiphrenic diverticulum)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will focus on clinical issues surrounding Zenker's diverticula. One of the clinical manifestations of Zenker's diverticulum is oropharyngeal dysphagia, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for the diagnosis and treatment of oropharyngeal dysphagia (including a discussion on Zenker's diverticulum) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/4\">",
"     4",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zenker's diverticula (ZD) and epiphrenic diverticula are thought to be caused by motor abnormalities of the esophagus. In contrast, traction diverticula were originally thought to be due to scarring and traction on the walls of the esophagus (hence the name) from external inflammatory processes (such as fungal infections or tuberculosis). However, more recent evidence has demonstrated that many mid-esophageal diverticula are also associated with esophageal motility abnormalities including spasm, achalasia, lower esophageal sphincter hypertension, or nonspecific abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In our institution, the majority of mid-esophageal diverticula have been seen in patients who had tuberculosis 20 to 30 years earlier.",
"   </p>",
"   <p>",
"    ZD emerge from a defect in the muscular wall of the hypopharynx in a natural area of weakness known as Killian's triangle, which is formed by the oblique fibers of the inferior pharyngeal constrictor muscle and the cricopharyngeal sphincter. Autopsy series suggest Killian's triangle is more prevalent in males (60 percent) and is associated with the dimensions of the body and with the length and the descensus of the larynx [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/7\">",
"     7",
"    </a>",
"    ]. Evagination of the sphincter is thought to result from chronic increased pressure on the weakened area, which may be due to two causes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High intrabolus pressures during swallowing",
"     </li>",
"     <li>",
"      Resistance to swallowing due to abnormalities of the UES",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data supporting these hypotheses have been based upon manometric pressure recordings in patients with ZD. However, studies evaluating UES pressures in these patients have been inconsistent. The technical challenges of manometric data collection for EUS function may account for such varied results. They may also reflect potentially heterogeneous defects that could result in a ZD and the variable methods used to record UES pressures. Furthermore, the presence of a diverticulum, particularly a larger one, may distort the pressure profile such that it no longer represents the conditions that originally favored diverticulum formation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/8\">",
"     8",
"    </a>",
"    ]. The AGA technical review for the clinical use of esophageal manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/9\">",
"     9",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The results of several studies illustrate the types of observations made in patients with ZD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, manometric and videoradiographic studies were compared in 14 patients with ZD and nine healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/10\">",
"       10",
"      </a>",
"      ]. The timing of pharyngeal contractions and sphincter relaxation, opening and closure, and relaxation of the UES were similar. However, the UES opening was significantly reduced and intrabolus pressure increased in patients with ZD compared with controls in the sagittal and transverse dimensions.",
"     </li>",
"     <li>",
"      A separate study from the same authors compared cricopharyngeus muscle strips from 14 patients with ZD to 10 controls (obtained at autopsy) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients with ZD had marked differences in muscle fibers including fibroadipose tissue replacement and fiber degeneration. It was concluded that these structural changes were responsible for the diminished UES opening in patients with ZD.",
"     </li>",
"     <li>",
"      Several other studies have demonstrated a variety of abnormalities of UES function but the results have been conflicting; reported UES abnormalities have included increased pressure, decreased pressure, uncoordinated contraction, premature contraction, and relaxation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report found that of 20 patients with ZD who underwent surgical correction, all had evidence of esophageal dysmotility; the majority of these patients also had gastroesophageal reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/13\">",
"       13",
"      </a>",
"      ]. These results suggested that ZD was caused by general esophageal dysmotility rather than UES dysfunction. In support of this observation is our own experience in which we have noted the presence of Barrett's esophagus in approximately 15 to 20 percent of patients with ZD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/14\">",
"       14",
"      </a>",
"      ]. The association with gastroesophageal reflux has been suggested since the 1970s, following a report of an increased incidence of hiatal hernia in patients with a ZD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/15\">",
"       15",
"      </a>",
"      ]. A possible explanation for the association could be acid-induced esophageal shortening, resulting in a gap between the cricopharyngeus muscle and the pharyngeal constrictors, which permits herniation caudal to the constrictors [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Considering these observations together, a reasonable hypothesis for the development of ZD is that it occurs in a variety of circumstances predisposing to herniation within Killian's triangle, such as abnormal esophageal motility, esophageal shortening, or disorders associated with UES dysfunction. The increased intrabolus pressures observed in patients with ZD may be secondary to impaired bolus passage in combination with or as a result of gastroesophageal reflux disease. An unanswered question is how spasms of the UES provoked by acid reflux could lead to increased intrabolus pressures during swallowing, given that swallowing is often distinct from episodes of acid reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zenker's diverticula are usually discovered in older adults, although they have been described in children. Most patients present after the age of 60 (often above age 75), having had symptoms ranging from weeks to years. For unclear reasons, the majority of patients are male [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient dysphagia may be noted early in the course. The openings of large ZD are often aligned with the axis of the pharynx such that food is preferentially diverted into the diverticulum. When the pharyngeal sac becomes large enough to retain contents such as mucus, pills, sputum, and food, the patient may complain of pulmonary aspiration, foul breath, gurgling in the throat, appearance of a mass in the neck, or regurgitation of food into the mouth. Severe cachexia can be present in patients with longstanding dysphagia. The ZD may become so large that its retained contents may push anteriorly and completely obstruct the esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zenker's diverticula are usually diagnosed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    examinations (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52971 \" href=\"UTD.htm?20/38/21102\">",
"     image 1",
"    </a>",
"    ). In some patients, the entire first glass of barium taken will disappear into the confines of an especially large diverticulum. However, small diverticula can be missed if they are superimposed on the main column of barium in the esophagus. This can be avoided by rotating the patient during the examination. In our experience, a second diverticulum is present in approximately 1 to 2 percent of patients but is usually much smaller than the first. Esophageal manometry is typically not required; however, it may help to illuminate the pathogenesis of the diverticulum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, ZD can produce a variety of symptoms and complications such as aspiration pneumonia. In addition, a very rare complication is the occurrence of a carcinoma in the diverticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/17\">",
"     17",
"    </a>",
"    ]. Ulceration and bleeding due to retained medication has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caution must be used during endoscopy or passage of nasogastric tubes because of the risk of inadvertent perforation of the diverticulum. In patients with a known ZD, it is advisable to intubate the esophagus under direct visualization. Endoscopes requiring blind passage (such as side-viewing endoscopes used for ERCP, endoscopic ultrasound endoscopes, and probes for transesophageal cardiac ultrasound) can be passed after an initial endoscopy with a forward-viewing endoscope and passage of an overtube or a guidewire [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/20\">",
"     20",
"    </a>",
"    ]. Several reports suggested that video capsule endoscopy should not be performed in the presence of a Zenker's diverticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment of symptomatic ZD has been surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. However, nonsurgical minimally invasive methods are being used increasingly. Although flexible endoscopic treatment has been heralded as potentially being a cost-effective minimally invasive approach, limited numbers of endoscopists have been trained in this technique, particularly in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/8,27-29\">",
"     8,27-29",
"    </a>",
"    ]. However, otolaryngology specialists in the United States appear to be increasingly adopting endoscopic diverticulectomy as the procedure of choice for the treatment of Zenker's diverticula [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four methods of surgical correction of a ZD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A two-stage operation involving mobilization of the ZD and excision at a later stage when granulation tissue has formed around the ZD",
"     </li>",
"     <li>",
"      Excision of the ZD in one step",
"     </li>",
"     <li>",
"      Cricopharyngeal myotomy, leaving the ZD undisturbed",
"     </li>",
"     <li>",
"      Cricopharyngeal myotomy with diverticulectomy or diverticulopexy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One stage cricopharyngeal myotomy and diverticulectomy has been the preferred approach in patients who are good surgical candidates. The efficacy of myotomy is supported by a number of surgical series in which excellent or very good responses have been observed in 80 to 100 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/23,26,31-36\">",
"     23,26,31-36",
"    </a>",
"    ]. Recurrence rates for symptomatic diverticula of 15 to 35 percent confirm the importance of cricopharyngeal myotomy performed at the time of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. These results have formed the basis for recommending this approach in the treatment of ZD in a technical review for oropharyngeal dysphagia issued by the American Gastroenterological Association [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/39\">",
"     39",
"    </a>",
"    ], which can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A major concern related to diverticulectomy is the potential for causing mediastinitis. Thus, in high-risk surgical patients, cricopharyngeal myotomy and diverticulopexy has become the treatment of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. The procedure involves suspension of the lumen of the diverticulum in the caudal direction such that the orifice is directed away from the hypopharynx, thereby preventing the entry of food and secretions.",
"   </p>",
"   <p>",
"    Complications of surgical procedures for ZD include mediastinitis, vocal cord paralysis, pharyngocutaneous fistula, esophageal stenosis, and a recurrent or persistent ZD. The overall complication rate in one series of 900 patients treated with one-stage diverticulectomy without myotomy was less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/17\">",
"     17",
"    </a>",
"    ]. Complications were more likely in patients with comorbid illnesses and large diverticula. Postoperatively, radiographic recurrence appears to be more common than symptomatic recurrence. Reoperation for a ZD is associated with high perioperative morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intraluminal approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticulostomy and myotomy have been performed with an intraluminal approach in some centers since the 1960s. The technique involves coagulation of the bridge between the esophagus and the diverticulum with insulated forceps, and subsequent division of the coagulated tissue with a diathermic knife [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/40\">",
"     40",
"    </a>",
"    ]. The procedure, performed through a rigid endoscope under general anesthesia, has been accomplished using a variety of coagulation and cutting devices including a CO2 laser [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/41\">",
"     41",
"    </a>",
"    ]. Good results have been reported in up to 90 percent of patients. An advantage of this approach is that it is easier to repeat (in case of treatment failure or recurrence) compared with an open procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variation to this approach is the stapler-assisted method (endoscopic stapler esophagodiverticulostomy [ESED]). At least 15 studies of ESED have been published since an initial description in 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/8,43\">",
"     8,43",
"    </a>",
"    ]. Overall, these data suggest that the stapling technique is safe and effective in the short-term, with a significant reduction in hospital stay and convalescence when compared with other surgical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/8,43-47\">",
"     8,43-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of applications of staples that should be applied may depend upon the size of the diverticulum. Most reports used two applications of staples. However, single application appears to be sufficient for diverticula that are approximately 2 to 2.5 cm deep, while two applications are generally needed for larger diverticula. On the other hand, some authors have suggested that stapling is a relative contraindication for large diverticula since the resultant large pharyngeal cavities may not empty completely [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authorities have concluded that ESED affords better symptomatic relief than endoscopic techniques, especially in patients with small diverticula [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/38\">",
"     38",
"    </a>",
"    ]. On the other hand, others have maintained that diverticula smaller than 2 cm cannot be successfully treated with this method [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/44\">",
"     44",
"    </a>",
"    ]. In patients with a small diverticulum, an external sphincterotomy alone is generally preferred by otolaryngologists [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/48\">",
"     48",
"    </a>",
"    ]. A modification of the stapler-assisted method has been described, which enables this technique to be used for smaller diverticula as well [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential limitation of the stapling device is that it may be difficult to place correctly due to the narrowness of the pharyngeal tube. One report suggested that the risk of incorrect placement of the staples could be reduced by placing a second tube in the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/50\">",
"     50",
"    </a>",
"    ]. Despite these innovations, not all patients are suitable candidates; in particular, the procedure cannot be performed in those whose anatomy precludes exposure of the diverticulum (with a \"Weerda\" laryngoscope that is used for the procedure) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one study has compared the total costs of open surgery versus intraluminal stapling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/51\">",
"     51",
"    </a>",
"    ]. Costs of instrumentation were higher with stapling, but the shorter hospital stay reduced the overall costs significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/51\">",
"     51",
"    </a>",
"    ]. Long-term follow-up, including the number of repeat procedures, is required to fully understand issues related to cost-effectiveness.",
"   </p>",
"   <p>",
"    The durability of response to the stapled approach is unsettled. A review of ESED literature and experience in more than 150 consecutive cases identified a recurrence rate of 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for hyperextension of the neck, dental injuries, perforations, and recurrent laryngeal nerve paralysis are concerns with this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/53\">",
"     53",
"    </a>",
"    ]. Surgical exposure in rigid endoscopic repair of Zenker's diverticulum fails in approximately 30 percent of patients and is more likely in patients with short necks, decreased hyomental distance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FLEXIBLE ENDOSCOPIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rigid endoscopic approach used by otolaryngologists was a major advance in the 1950s. However, surgery is not possible in many symptomatic elderly patients who are poor surgical candidates. Despite the availability of flexible endoscopy for more than 30 years, the first reports using the flexible endoscope for treatment of ZD were not published until 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. The same principle used in the rigid endoscopic approach can be applied during flexible endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique involves",
"    <span class=\"nowrap\">",
"     coagulation/cutting",
"    </span>",
"    of the bridge, especially the cricopharyngeal muscle, between the esophagus and the diverticulum. The objective is to create an overflow from the ZD to the esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;At our institution, all patients with minor or major complaints related to the diverticulum are considered to be eligible for flexible endoscopic treatment. However, we explain the extraluminal alternatives, especially in those younger than 50 to 60 years of age. Diverticulectomy in combination with cricopharyngeal myotomy may be preferred in the younger patients. Most of the patients referred for the flexible approach are poor surgical candidates due to comorbid diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Equipment and personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution video-endoscopes are preferred, although the procedure can be performed using older fiberoptic endoscopes. We generally use argon plasma coagulation (APC) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/14\">",
"     14",
"    </a>",
"    ], but monopolar forceps or needle-knives can be used as an alternative. A flexible guidewire, gastric lavage tubes (CH 14-18) and a needle-knife should be available. One or, if possible, two experienced endoscopy nurses are needed to assist in the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our institution, the procedure is performed under conscious sedation, with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is an outstanding alternative if local experience and regulations permit. A key element is adequate exposure of the ZD bridge in the endoscopic field. This has usually been achieved by insertion of a nasogastric tube (NGT), which is left in situ during the procedure. The NGT protects the contralateral esophageal wall from thermal injury during sectioning of the ZD bridge (",
"    <a class=\"graphic graphic_picture graphicRef74677 \" href=\"UTD.htm?25/36/26177\">",
"     picture 1",
"    </a>",
"    ). However, exposure of the bridge with the NGT can be suboptimal, particularly in small diverticula or in those with a distorted axis with respect to the esophageal lumen. To overcome this limitation, a plastic overtube (Cook Endoscopy, Winston Salem, NC) has been designed based upon the otolaryngology experience with the rigid diverticuloscope. The device has a double duck bill extremity that fits the anterior esophageal wall and the posterior wall of the diverticulum, leaving the bridge in the center of the endoscopic field. Experience with this device has been promising [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report of 10 patients demonstrated the successful use of a transparent, oblique end hood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/60\">",
"     60",
"    </a>",
"    ]. The purpose of the hood (which is 15 mm long and has an oblique-end transparent cap at the endoscope tip) is to permit a better view of the septum. Whether it has any advantages compared with other approaches is unclear. One study compared the use of the flexible diverticuloscope with the use of a transparent cap [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/61\">",
"     61",
"    </a>",
"    ]. A needle-knife was used for diverticulectomy. Remission rates were higher in the diverticuloscope group, while complications occurred more often in the cap-assisted group. Median procedure time was almost double in the cap-assisted group.",
"   </p>",
"   <p>",
"    With the APC-probe we begin 2 to 3 cm below the top of the bridge and withdraw the endoscope while applying APC (ERBE VIO 300D, forced 50 W) (",
"    <a class=\"graphic graphic_picture graphicRef55531 \" href=\"UTD.htm?25/45/26323\">",
"     picture 2",
"    </a>",
"    ). Alternatively, APC can be applied to the esophageal",
"    <span class=\"nowrap\">",
"     wall/Zenker",
"    </span>",
"    wall and then secondary applied to the top of the bridge. The narrow space and reflection of the light from APC can pose a challenge when trying to maintain an optimal field particularly when using Olympus-video-endoscopes, which are sensitive to interference from the ERBE generator. Small diverticula can be treated easily with this technique.",
"   </p>",
"   <p>",
"    The technique with the needle-knife requires a longer learning-curve. In addition, it may pose a higher risk in patients who are coughing compared with using monopolar forceps or APC. On the other hand, the needle-knife is an attractive approach in patients in whom an excellent view can be obtained and in whom the bridge appears to be atrophic. Alternatively, studies suggest that a hook-knife (a device developed for submucosal dissection) can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/62\">",
"     62",
"    </a>",
"    ]. The harmonic scalpel, which uses coaptive coagulation to dissect the diverticulum, has been demonstrated to be safe and feasible in small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/63\">",
"     63",
"    </a>",
"    ]. Larger studies are needed to further evaluate this technique. Flexible bipolar hemostasis forceps developed for natural orifice transluminal surgery (NOTES) has been shown to be easy to use in an animal model for ZD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using a knife or monopolar forceps, the initial cut or coagulation is made at the top of the ZD-bridge. The transverse fibers of the cricopharyngeal muscle should be visualized. The",
"    <span class=\"nowrap\">",
"     cutting/coagulation",
"    </span>",
"    should be performed in the midline of the bridge. We use only coagulation current and",
"    <strong>",
"     not",
"    </strong>",
"    cut or endo cut current. If possible, we try to keep the esophageal and diverticular lumens under direct vision, which usually becomes easier after the initial cuts have been made. Early in the learning curve it is prudent to divide 2 to 3 cm of the ZD-bridge and then stop and repeat the procedure the next day.",
"   </p>",
"   <p>",
"    If microperforations are suspected, the bottom of the cut can be closed using endoscopically placed clips. These can also be used to achieve hemostasis if bleeding occurs.",
"   </p>",
"   <p>",
"    When the procedures are difficult, we leave the NGT in place for two hours, but only perform contrast radiography in case of suspected perforation. If no perforation is suspected, we remove the NGT and oral fluid intake is started. The diet is advanced within the next few days. We do not feel that it is necessary to obtain a contrast study after subsequent treatments. With increasing experience in different centers, endoscopic diverticulostomy is becoming an outpatient procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Success rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible endoscopic approaches to Zenker's diverticulum are currently performed all over the world. The following illustrate the range of findings in the largest series.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report described 47 patients in whom treatment was performed using the needle-knife technique described above [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/57\">",
"       57",
"      </a>",
"      ]. Most patients underwent more than one treatment session (mean 2.2). The majority (96 percent) had no dysphagia or only mild occasional dysphagia during the postoperative course. There were no major complications. A success rate of 84 percent after 26 months follow-up was reported in a later series that also used the needle-knife technique [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/65\">",
"       65",
"      </a>",
"      ]. However, complications occurred in 23 percent of patients.",
"     </li>",
"     <li>",
"      Another series described an approach using APC in 41 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/66\">",
"       66",
"      </a>",
"      ]. Patients required a mean of three sessions, which was associated with a clinical success rate of 95 percent. One perforation occurred. Of the 34 patients whose follow-up was greater than six months, five experienced recurrence, but were asymptomatic after retreatment.",
"     </li>",
"     <li>",
"      A series of 21 patients were treated with monopolar forceps, using a flexible endoscope with a transparent cap attached to the tip of the endoscope [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/67\">",
"       67",
"      </a>",
"      ]. Two patients needed two sessions, while the remaining 19 patients were asymptomatic after one session. Only one patient suffered from transient cervical emphysema. Follow-up was three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the available data demonstrate long-term success rates from 29 percent (cap-assisted needle-knife) to 100 percent (monopolar forceps). Complication rates have varied from 5 percent (monopolar forceps) to 23 percent (needle-knife). However, these were all case series. There are no prospective studies comparing APC, monopolar forceps, or needle-knife.",
"   </p>",
"   <p>",
"    Our experience in over 500 patients using the techniques described above has been similar [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/14\">",
"     14",
"    </a>",
"    ]. Virtually all patients have shown marked improvement in symptoms after one to two treatments, a result that is particularly remarkable given the comorbidities in the population treated and that approximately 15 percent had previously been treated by surgery. Four patients, all above 95 years of age, died within 30 days of treatment (approximately 1 percent): one from bleeding from the ZD bridge, and the other three from causes that were probably unrelated to the procedure (cerebrovascular accident in two and a pulmonary embolism in the third). Subcutaneous emphysema was observed in approximately 5 percent of patients, particularly those who were coughing. It typically resolved within 24 to 72 hours without adverse consequences. Oozing of blood from the bridge was seen in less than 3 percent and was unlikely when using coagulation current with the needle-knife. Oozing was also easy to control with APC.",
"   </p>",
"   <p>",
"    Our current approach is to treat older patients in the hospital, then again six to eight weeks later as outpatients. The procedure is subsequently repeated only in those with recurrent symptoms. Follow-up radiologic studies of patients treated endoscopically for ZD are generally not indicated to evaluate postoperative results since they do not correlate with symptoms of dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/8\">",
"     8",
"    </a>",
"    ]. After endoscopic treatment, the diverticulum will still remain visible on radiographs as a residual pouch [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious complication is perforation of the GI tract. Perforation of a hollow viscous has traditionally been treated surgically. However, there has been ongoing debate regarding conservative management of esophageal perforations, but data are limited. Nonsurgical therapy generally includes administration of broad spectrum antibiotics, elimination of oral intake, parenteral nutrition, and nasogastric drainage. One report described a potential benefit from aggressive endoscopic lavage of mediastinal abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/68\">",
"     68",
"    </a>",
"    ]. More studies are needed addressing how complications should be managed.",
"   </p>",
"   <p>",
"    Other complications have been mainly related to conscious sedation, such as periprocedural myocardial infarction and pulmonary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Training",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rarity of ZD, together with the different techniques available for the endoscopic treatment of ZD, make training difficult. We suggest that treatment of ZD be performed only by experienced gastroenterologists who perform diverticulectomy at least 25 to 50 times a year.",
"   </p>",
"   <p>",
"    An animal training model for endoscopic treatment of ZD has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29512/abstract/69\">",
"     69",
"    </a>",
"    ]. All domestic pigs have a pharyngeal diverticulum. The mean depth of these diverticula is 2.7 cm (range 1.3 to 5.0 cm). The diverticula resemble human ZD endoscopically and radiologically. The septum of the pig's diverticula also contains muscle, fibrous tissue, and fat, like the human ZD septum. Although no diverticulectomies in the pig model have been described, it is likely that this porcine model will become important for training endoscopists in the different flexible endoscopic techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The precise cause of Zenker's diverticulum (ZD) remains unsettled but it occurs in a variety of circumstances predisposing to herniation within Killian's triangle, such as abnormal esophageal motility, esophageal shortening, or disorders associated with UES dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of patients with Zenker's diverticula should consider the availability of local expertise. Experience is important, regardless of which method is used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest rigid or flexible endoscopic treatment be considered in centers with a trained endoscopist who has demonstrated favorable outcomes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Exceptions are young patients with large diverticula (see below). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Flexible endoscopic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Referral for flexible endoscopic treatment should be considered in symptomatic patients who are poor candidates for a traditional surgical approach and for other patients in whom surgery or rigid endoscopic approach is not an option. Patients with small diverticula, for example, can be treated readily with a flexible endoscopic approach in contrast to the endoscopic stapler approach, which may not be feasible. The flexible endoscopic approach may also be an option for patients who developed recurrent symptoms following surgery. Whether the rigid or flexible endoscopic approaches should be used as initial therapy in younger patients who would otherwise be good surgical candidates for open treatment is unclear. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main advantage of the flexible endoscopic approach is the ease with which it can be performed without the need for general anesthesia, which is required for the surgical and rigid endoscopic approaches. Complications for the rigid and flexible approaches appear to be comparable. Because of its association with shorter operation times, shorter or no hospital stays, rapid resumption of oral intake, and easy access in case of recurrence, endoscopic diverticulostomy and myotomy, either rigid or flexible endoscopic, is the treatment of choice for ZD in selected patients.",
"     </li>",
"     <li>",
"      There has been insufficient follow-up to assess the relative efficacy of the different endoscopic approaches, although emerging evidence suggests that the results are comparable to surgical treatment. Recurrent symptoms may develop if a myotomy has been inadequate or if there is reapposition of the cut muscle edges. In our experience, recurrence is more likely in patients with wide diverticula. In our and others' experience, the motor abnormality of the hypopharynx persists after treatment and myotomy may impair the propulsive activity of the hypopharynx. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Success rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients younger than 50 to 60 years of age with large diverticula, we suggest open surgery because large diverticula after intraluminal treatment (stapler, needle-knife, or APC) with large \"pharyngeal\" cavities do not empty completely (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment options need to be tailored to the needs of the patient and to the resources and skills available in the local situation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/1\">",
"      Siddiq MA, Sood S, Strachan D. Pharyngeal pouch (Zenker's diverticulum). Postgrad Med J 2001; 77:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/2\">",
"      Ludlow A. A case of obstructed deglutition from a preternatural dilatation of a bagformed in pharynx. Med Observations Inquiries 1767; 3:85.",
"     </a>",
"    </li>",
"    <li>",
"     Zenker FA, von Ziemssen H. Krankheiten des Oesophagus. In: Handbuch der specielen Pathologie und Therapie, Von Ziemssen H (Ed), FC Vogel, Leipzig 1877. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/4\">",
"      American Gastroenterological Association medical position statement on management of oropharyngeal dysphagia. Gastroenterology 1999; 116:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/5\">",
"      D'Ugo D, Cardillo G, Granone P, et al. Esophageal diverticula. Physiopathological basis for surgical management. Eur J Cardiothorac Surg 1992; 6:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/6\">",
"      F&eacute;k&eacute;te F, Vonns C. Surgical management of esophageal thoracic diverticula. Hepatogastroenterology 1992; 39:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/7\">",
"      Anagiotos A, Preuss SF, Koebke J. Morphometric and anthropometric analysis of Killian's triangle. Laryngoscope 2010; 120:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/8\">",
"      Sen P, Bhattacharyya AK. Endoscopic stapling of pharyngeal pouch. J Laryngol Otol 2004; 118:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/9\">",
"      Pandolfino JE, Kahrilas PJ, American Gastroenterological Association. AGA technical review on the clinical use of esophageal manometry. Gastroenterology 2005; 128:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/10\">",
"      Cook IJ, Gabb M, Panagopoulos V, et al. Pharyngeal (Zenker's) diverticulum is a disorder of upper esophageal sphincter opening. Gastroenterology 1992; 103:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/11\">",
"      Cook IJ, Blumbergs P, Cash K, et al. Structural abnormalities of the cricopharyngeus muscle in patients with pharyngeal (Zenker's) diverticulum. J Gastroenterol Hepatol 1992; 7:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/12\">",
"      Fulp SR, Castell DO. Manometric aspects of Zenker's diverticulum. Hepatogastroenterology 1992; 39:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/13\">",
"      Resouly A, Braat J, Jackson A, Evans H. Pharyngeal pouch: link with reflux and oesophageal dysmotility. Clin Otolaryngol Allied Sci 1994; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/14\">",
"      Mulder CJ, Costamagna G, Sakai P. Zenker's diverticulum: treatment using a flexible endoscope. Endoscopy 2001; 33:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/15\">",
"      Hunt PS, Connell AM, Smiley TB. The cricopharyngeal sphincter in gastric reflux. Gut 1970; 11:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/16\">",
"      Sasaki CT, Ross DA, Hundal J. Association between Zenker diverticulum and gastroesophageal reflux disease: development of a working hypothesis. Am J Med 2003; 115 Suppl 3A:169S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/17\">",
"      Payne WS. The treatment of pharyngoesophageal diverticulum: the simple and complex. Hepatogastroenterology 1992; 39:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/18\">",
"      Kensing KP, White JG, Korompai F, Dyck WP. Massive bleeding from a Zenker's diverticulum: case report and review of the literature. South Med J 1994; 87:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/19\">",
"      Sharma R, DeCross AJ. Zenker's diverticulitis secondary to alendronate ingestion: a rare cause of recurrent dysphagia. Gastrointest Endosc 2011; 73:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/20\">",
"      Dickey W, Porter KG. Duodenoscope intubation of the oesophagus in the presence of pharyngeal pouch made possible by an overtube. Endoscopy 1995; 27:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/21\">",
"      Ford RM, Affronti J, Cohen R, et al. Zenker's diverticulum: a contraindication for wireless capsule endoscopy? J Clin Gastroenterol 2005; 39:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/22\">",
"      Knapp AB, Ladetsky L. Endoscopic retrieval of a small bowel enteroscopy capsule lodged in a Zenker's diverticulum. Clin Gastroenterol Hepatol 2005; 3:xxxiv.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/23\">",
"      Witterick IJ, Gullane PJ, Yeung E. Outcome analysis of Zenker's diverticulectomy and cricopharyngeal myotomy. Head Neck 1995; 17:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/24\">",
"      Lerut T, van Raemdonck D, Guelinckx P, et al. Zenker's diverticulum: is a myotomy of the cricopharyngeus useful? How long should it be? Hepatogastroenterology 1992; 39:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/25\">",
"      Konowitz PM, Biller HF. Diverticulopexy and cricopharyngeal myotomy: treatment for the high-risk patient with a pharyngoesophageal (Zenker's) diverticulum. Otolaryngol Head Neck Surg 1989; 100:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/26\">",
"      Barthlen W, Feussner H, Hannig C, et al. Surgical therapy of Zenker's diverticulum: low risk and high efficiency. Dysphagia 1990; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/27\">",
"      Feussner H. Reducing treatment of Zenker's diverticulum to the essentials: the flexible endoscopic approach. Endoscopy 1995; 27:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/28\">",
"      Grund KE. Argon plasma coagulation (APC): ballyhoo or breakthrough? Endoscopy 1997; 29:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/29\">",
"      Bremner CG, DeMeester TR. Endoscopic treatment of Zenker's diverticulum. Gastrointest Endosc 1999; 49:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/30\">",
"      Altman JI, Genden EM, Moche J. Fiberoptic endoscopic-assisted diverticulotomy: a novel technique for the management of Zenker's diverticulum. Ann Otol Rhinol Laryngol 2005; 114:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/31\">",
"      Gagic NM. Cricopharyngeal myotomy. Can J Surg 1983; 26:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/32\">",
"      Duranceau A, Rheault MJ, Jamieson GG. Physiologic response to cricopharyngeal myotomy and diverticulum suspension. Surgery 1983; 94:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/33\">",
"      Bonavina L, Khan NA, DeMeester TR. Pharyngoesophageal dysfunctions. The role of cricopharyngeal myotomy. Arch Surg 1985; 120:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/34\">",
"      Lerut T, Van Raemdonck D, Guelinckx P, et al. Pharyngo-oesophageal diverticulum (Zenker's). Clinical, therapeutic and morphological aspects. Acta Gastroenterol Belg 1990; 53:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/35\">",
"      Lindgren S, Ekberg O. Cricopharyngeal myotomy in the treatment of dysphagia. Clin Otolaryngol Allied Sci 1990; 15:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/36\">",
"      Shaw DW, Cook IJ, Jamieson GG, et al. Influence of surgery on deglutitive upper oesophageal sphincter mechanics in Zenker's diverticulum. Gut 1996; 38:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/37\">",
"      Aggerholm K, Illum P. Surgical treatment of Zenker's diverticulum. J Laryngol Otol 1990; 104:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/38\">",
"      Gutschow CA, Hamoir M, Rombaux P, et al. Management of pharyngoesophageal (Zenker's) diverticulum: which technique? Ann Thorac Surg 2002; 74:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/39\">",
"      Cook IJ, Kahrilas PJ. AGA technical review on management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/40\">",
"      DOHLMAN G, MATTSSON O. The endoscopic operation for hypopharyngeal diverticula: a roentgencinematographic study. AMA Arch Otolaryngol 1960; 71:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/41\">",
"      van Overbeek JJ, Hoeksema PE, Edens ET. Microendoscopic surgery of the hypopharyngeal diverticulum using electrocoagulation or carbon dioxide laser. Ann Otol Rhinol Laryngol 1984; 93:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/42\">",
"      van Overbeek JJ. Meditation on the pathogenesis of hypopharyngeal (Zenker's) diverticulum and a report of endoscopic treatment in 545 patients. Ann Otol Rhinol Laryngol 1994; 103:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/43\">",
"      Collard JM, Otte JB, Kestens PJ. Endoscopic stapling technique of esophagodiverticulostomy for Zenker's diverticulum. Ann Thorac Surg 1993; 56:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/44\">",
"      Narne S, Cutrone C, Bonavina L, et al. Endoscopic diverticulotomy for the treatment of Zenker's diverticulum: results in 102 patients with staple-assisted endoscopy. Ann Otol Rhinol Laryngol 1999; 108:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/45\">",
"      Scher RL, Richtsmeier WJ. Long-term experience with endoscopic staple-assisted esophagodiverticulostomy for Zenker's diverticulum. Laryngoscope 1998; 108:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/46\">",
"      Peracchia A, Bonavina L, Narne S, et al. Minimally invasive surgery for Zenker diverticulum: analysis of results in 95 consecutive patients. Arch Surg 1998; 133:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/47\">",
"      Verhaegen VJ, Feuth T, van den Hoogen FJ, et al. Endoscopic carbon dioxide laser diverticulostomy versus endoscopic staple-assisted diverticulostomy to treat Zenker's diverticulum. Head Neck 2011; 33:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/48\">",
"      van Overbeek JJ. Pathogenesis and methods of treatment of Zenker's diverticulum. Ann Otol Rhinol Laryngol 2003; 112:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/49\">",
"      Mortensen M, Schaberg MR, Genden EM, Woo P. Transoral resection of short segment Zenker's diverticulum and cricopharyngeal myotomy: an alternative minimally invasive approach. Laryngoscope 2010; 120:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/50\">",
"      Schipper J, Weerda N, Aschendorff A, et al. [Endoscopic assisted endoluminal stapler-diverticulotomy of Zenker diverticulum]. Laryngorhinootologie 2005; 84:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/51\">",
"      Smith SR, Genden EM, Urken ML. Endoscopic stapling technique for the treatment of Zenker diverticulum vs standard open-neck technique: a direct comparison and charge analysis. Arch Otolaryngol Head Neck Surg 2002; 128:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/52\">",
"      Chang CY, Payyapilli RJ, Scher RL. Endoscopic staple diverticulostomy for Zenker's diverticulum: review of literature and experience in 159 consecutive cases. Laryngoscope 2003; 113:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/53\">",
"      Mirza S, Dutt SN, Irving RM. Iatrogenic perforation in endoscopic stapling diverticulotomy for pharyngeal pouches. J Laryngol Otol 2003; 117:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/54\">",
"      Bloom JD, Bleier BS, Mirza N, et al. Factors predicting endoscopic exposure of Zenker's diverticulum. Ann Otol Rhinol Laryngol 2010; 119:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/55\">",
"      Ishioka S, Sakai P, Maluf Filho F, Melo JM. Endoscopic incision of Zenker's diverticula. Endoscopy 1995; 27:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/56\">",
"      Mulder CJ, den Hartog G, Robijn RJ, Thies JE. Flexible endoscopic treatment of Zenker's diverticulum: a new approach. Endoscopy 1995; 27:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/57\">",
"      Hashiba K, de Paula AL, da Silva JG, et al. Endoscopic treatment of Zenker's diverticulum. Gastrointest Endosc 1999; 49:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/58\">",
"      Wahab PJ, Mulder CJ, den Hartog G, Thies JE. Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy 1997; 29:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/59\">",
"      Evrard S, Le Moine O, Hassid S, Devi&egrave;re J. Zenker's diverticulum: a new endoscopic treatment with a soft diverticuloscope. Gastrointest Endosc 2003; 58:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/60\">",
"      Sakai P, Ishioka S, Maluf-Filho F, et al. Endoscopic treatment of Zenker's diverticulum with an oblique-end hood attached to the endoscope. Gastrointest Endosc 2001; 54:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/61\">",
"      Costamagna G, Iacopini F, Tringali A, et al. Flexible endoscopic Zenker's diverticulotomy: cap-assisted technique vs. diverticuloscope-assisted technique. Endoscopy 2007; 39:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/62\">",
"      Repici A, Pagano N, Romeo F, et al. Endoscopic flexible treatment of Zenker's diverticulum: a modification of the needle-knife technique. Endoscopy 2010; 42:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/63\">",
"      Hondo FY, Maluf-Filho F, Giordano-Nappi JH, et al. Endoscopic treatment of Zenker's diverticulum by harmonic scalpel. Gastrointest Endosc 2011; 74:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/64\">",
"      Rieder E, Martinec DV, Dunst CM, Swanstr&ouml;m LL. Flexible endoscopic Zenkers diverticulotomy with a novel bipolar forceps: a pilot study and comparison with needleknife dissection. Surg Endosc 2011; 25:3273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/65\">",
"      Vogelsang A, Preiss C, Neuhaus H, Schumacher B. Endotherapy of Zenker's diverticulum using the needle-knife technique: long-term follow-up. Endoscopy 2007; 39:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/66\">",
"      Rabenstein T, May A, Michel J, et al. Argon plasma coagulation for flexible endoscopic Zenker's diverticulotomy. Endoscopy 2007; 39:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/67\">",
"      Christiaens P, De Roock W, Van Olmen A, et al. Treatment of Zenker's diverticulum through a flexible endoscope with a transparent oblique-end hood attached to the tip and a monopolar forceps. Endoscopy 2007; 39:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/68\">",
"      Hookey LC, Le Moine O, Devi&eacute;re J. Successful endoscopic management of a cervical pharyngeal perforation and mediastinal abscess. Gastrointest Endosc 2005; 61:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29512/abstract/69\">",
"      Seaman DL, de la Mora Levy J, Gostout CJ, et al. An animal training model for endoscopic treatment of Zenker's diverticulum. Gastrointest Endosc 2007; 65:1050.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2242 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29512=[""].join("\n");
var outline_f28_52_29512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intraluminal approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FLEXIBLE ENDOSCOPIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Equipment and personnel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Success rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2242|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/38/21102\" title=\"diagnostic image 1\">",
"      Zenkers diverticulum UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2242|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/36/26177\" title=\"picture 1\">",
"      Endoscopic view of Zenkers diverticulum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/45/26323\" title=\"picture 2\">",
"      Endoscopic diverticulectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=related_link\">",
"      Pathogenesis and clinical manifestations of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_52_29513="Diagnostic approach to lower gastrointestinal bleeding in children";
var content_f28_52_29513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to lower gastrointestinal bleeding in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29513/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29513/contributors\">",
"     Chris Ramsook, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29513/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29513/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29513/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29513/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29513/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/52/29513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower gastrointestinal bleeding in infants and children is commonly encountered in clinical practice, although its epidemiology has not been well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In one of the largest reports, rectal bleeding was the chief complaint in 0.3 percent of more than 40,000 patients presenting to the Boston Children's Emergency Department between September 1991 and August 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is divided into upper gastrointestinal hemorrhage (bleeding proximal to the ligament of Treitz) and lower gastrointestinal hemorrhage (bleeding distal to this point). Blood loss often is more marked in upper than in lower gastrointestinal bleeding (LGIB).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melena refers to the passage per rectum of black, tarry stools; it usually indicates upper gastrointestinal bleed (UGIB) or bleeding from the proximal small bowel.",
"     </li>",
"     <li>",
"      Hematochezia refers to the passage of bright red blood per rectum. It usually suggests LGIB, (typically from the colon) but can occur rarely with a massive UGIB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial question to consider in children presenting with LGIB is whether blood is truly present in the stool. Several foods and medicines may give stool a bloody appearance and create unnecessary anxiety in parents (",
"    <a class=\"graphic graphic_table graphicRef72978 \" href=\"UTD.htm?5/23/5499\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This confusion can be eliminated by using occult blood tests that rely on the catalytic splitting of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    by hemoglobin and its derivatives with a phenolic chromogen such as guaiac (Hemoccult II) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/7\">",
"     7",
"    </a>",
"    ]. However, false-positive results on peroxidase-based tests may result from ingestion of red meat, iron supplements, and peroxidase-containing vegetables (such as turnips, horseradish, broccoli, cauliflower, and cantaloupe). Patients usually are advised to avoid these items prior to elective stool sampling, a recommendation that is not feasible in those presenting acutely. As a result, nonguaiac-based methods to assess stool for blood have been developed. Examples include fecal hemoglobin measurement by immunodiffusion and fecal alpha-1 antitrypsin measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fecal hemoglobin test measures intact human hemoglobin and, thus, requires no dietary restrictions. Unfortunately, degradation of hemoglobin by bacteria often renders it unrecognizable by the antibody assay. Thus, the sensitivity and specificity are similar to the peroxidase-based test [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fecal alpha-1 antitrypsin measurement is used mostly to diagnose enteric protein loss because it resists bacterial degradation. However, it is also elevated in patients with gastrointestinal blood loss (upper or lower) in whom it has a sensitivity and specificity of 88 and 90 percent, compared to 68 and 73 percent, respectively, of the peroxidase-based test [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/8\">",
"     8",
"    </a>",
"    ]. An additional advantage of alpha-1 antitrypsin assay compared to the peroxidase-based tests is that it can identify patients with protein-losing enteropathy. The test is most useful in patients with recurrent red stools that are guaiac-negative or in those with a possible false-positive guaiac test result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertinent information from the history includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The duration and amount of bleeding",
"     </li>",
"     <li>",
"      The color of the blood",
"     </li>",
"     <li>",
"      Is there enough blood present to color the toilet water",
"     </li>",
"     <li>",
"      The consistency of accompanying stool",
"     </li>",
"     <li>",
"      Is the blood mixed in the stool or coating the outside",
"     </li>",
"     <li>",
"      Presence of blood on the toilet paper",
"     </li>",
"     <li>",
"      Does blood drip in the toilet after bowel movement",
"     </li>",
"     <li>",
"      Associated symptoms (such as abdominal pain, fever, diarrhea, weight loss and fatigue)",
"     </li>",
"     <li>",
"      A history of abnormal bleeding",
"     </li>",
"     <li>",
"      Past episodes of gastrointestinal hemorrhage",
"     </li>",
"     <li>",
"      Recent use of nonsteroidal antiinflammatory agents or any other medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination should investigate potential sites of bleeding. However, it is important to recognize that it may not be obvious on initial evaluation whether the site of bleeding is upper or lower, because stool color is insufficiently accurate to exclude an upper GI source. Thus, special attention should be given to examination of the posterior nose to exclude epistaxis as a source of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous bruising (abnormal hemostasis) and jaundice (hepatic failure) are important signs. An abdominal examination for signs of portal hypertension (ascites, abnormal venous pattern), masses, or tenderness can aid in the differential diagnosis. A rectal examination is important to exclude polyps or anal fissures and to obtain stool for guaiac testing. A spontaneously passed stool specimen can be tested for occult blood. The most convenient method in the toilet-trained child is to smear a small amount of stool from the toilet paper directly onto the guaiac card [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the past 40 years, the ability to localize bleeding from the gastrointestinal tract has improved greatly. As examples, in a report from 1964, a bleeding site could be localized in only 69 percent of 476 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/10\">",
"     10",
"    </a>",
"    ], compared to a report from 1984 in which a combination of physical examination, endoscopy, and air contrast enema permitted a definitive diagnosis in 94 percent of 103 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for particular diagnostic studies depends upon the clinical presentation, the age of the child, and the suspected diagnosis. A suggested approach based upon the clinical setting is presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CAUSES OF BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of lower gastrointestinal bleeding varies depending upon age. In the study of 104 children discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/1\">",
"     1",
"    </a>",
"    ] (in whom approximately one-half were younger than age 1 year) the most common diagnosis was allergic colitis, followed by anorectal fissure. The most common diagnoses in children between 12 to 60 months were infectious gastroenteritis and anorectal fissures. Bleeding was considered to be life-threatening in only four patients (4.2 percent), three of whom had ileocolic intussusception and one of whom had bleeding from a Meckel's diverticulum.",
"   </p>",
"   <p>",
"    The spectrum of causes is different in other parts of the world. In a report from India, for example, 24 percent of 85 children bled from amoebic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion will focus on the causes of bleeding most commonly seen in the United States during the neonatal period (younger than 1 month), infancy (1 month to 2 years), preschool (2 to 5 years), and the school-age period (older than 5 years) (",
"    <a class=\"graphic graphic_figure graphicRef58363 \" href=\"UTD.htm?37/30/38382\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NEONATAL PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common diagnoses to consider in newborns presenting with lower gastrointestinal bleeding are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Swallowed maternal blood",
"     </li>",
"     <li>",
"      Anorectal fissures",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis",
"     </li>",
"     <li>",
"      Malrotation with midgut volvulus",
"     </li>",
"     <li>",
"      Hirschsprung disease",
"     </li>",
"     <li>",
"      Coagulopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Swallowed maternal blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the immediate newborn period, rectal blood should be tested for fetal hemoglobin to exclude swallowed maternal blood or blood ingested from cracked nipples during breast feeding. This can be accomplished using the Apt test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Apt test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Apt test takes advantage of the different susceptibilities of HbA and HbF to alkali denaturation. Fresh stool is mixed with water (1:5) and centrifuged, and sodium hydroxide then is added to the supernatant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/11\">",
"     11",
"    </a>",
"    ]. Adult Hb changes to brown-yellow within two minutes (alkaline hematin), while fetal hemoglobin resists denaturation and retains its pink color. Stool with fetal blood exposed to air for &gt;30 minutes will give the same color change as adult hemoglobin. In cases in which the Apt test is inconclusive, a spectrophotometric assay can be used to quantify the color change. A fetal Hb &gt;50 percent indicates fetal blood and &lt;10 percent suggests maternal blood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anorectal fissures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal fissures are the most common cause of rectal bleeding in patients younger than 1 year. They are diagnosed easily by spreading the perineal skin to evert the anal canal. The history is of painful defecation with straining, grunting, and leg stiffening or back arching consistent with withholding behavior and streaks of bright red blood on the surface of the stools. When associated with constipation, they respond well to stool softeners and lubricants. When associated with diarrhea, healing is hastened by keeping the perineum clean and dry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Necrotizing enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing enterocolitis (NEC) is an acute illness of unclear etiology associated with intestinal necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most infants with NEC are born prematurely, approximately 13 percent of cases occur in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/8\">",
"     8",
"    </a>",
"    ]. The disease occurs predominantly in infants receiving enteral nutrition. NEC should be suspected in a newborn with nonspecific systemic signs, such as apnea, respiratory failure, lethargy, poor feeding, or temperature instability, and abdominal signs including distention, gastric retention (residual milk in the stomach before a feeding), tenderness, vomiting, diarrhea, and gross or occult lower gastrointestinal (GI) bleeding. Characteristic features in the supine abdominal radiograph are seen in most infants with suspected NEC An abnormal gas pattern with dilated loops of bowel that is consistent with ileus typically is seen in the early stages. Pneumatosis intestinalis, the hallmark of NEC, appears as bubbles of gas in the bowel wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Malrotation with midgut volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns who have malrotation with midgut volvulus typically present with abdominal distension, bilious emesis, and melena (in 10 to 20 percent of cases). Bilious emesis in the neonatal period should be assumed to represent a surgical emergency due to obstruction until proven otherwise.",
"   </p>",
"   <p>",
"    Malrotation is life-threatening and requires emergent evaluation and treatment. The diagnosis can be suggested by plain abdominal radiographs, but normal radiographs do not exclude it. A limited upper gastrointestinal (GI) contrast series is the best examination to visualize the duodenum; failure of the duodenum to cross the midline confirms the presence of malrotation. UGI contrast series should be performed, whenever possible, under fluoroscopy and by an experienced pediatric radiologist. The addition of a small bowel follow-through or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema to check for colonic malrotation is prudent in patients in whom the upper GI is normal but there is a high index of suspicion or signs of a distal bowel obstruction. The clinical presentation, evaluation, and management of malrotation are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20232?source=see_link\">",
"     \"Intestinal malrotation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hirschsprung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with Hirschsprung disease usually have delayed passage of meconium (&gt;48 hr) and abdominal distension. Other infants may present at several weeks of age with progressive constipation or diarrhea associated with abdominal distension. Only one-quarter of the patients have blood in the stool. Significant blood in the stool with distension in infants with Hirschsprung disease may be indicative of toxic megacolon and should be considered a medical emergency. In this situation the rectum needs to be immediately deflated by either rectal exam or the placement of a rectal tube. In older infants, the diagnosis should be suspected if the parents describe a history of constipation in which the infant depends upon mechanical or pharmacologic assistance to defecate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A contrast enema is used as an initial test. When diagnostic, the enema demonstrates marked dilation of the colon proximal to the aganglionic segment. Rectal motility studies can be confirmatory. The gold standard for diagnosis is the demonstration of complete absence of ganglion cells in the Meissner and the Auerbach plexus on a specimen of intestinal mucosa and submucosa obtained by suction biopsy or by surgical rectal biopsy if the results of suction biopsy are equivocal. Treatment generally is a diverting colostomy followed by a second-stage intestinal pull-through of innervated intestine, although outcomes with a primary pull-through appear to be comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhagic disease of the newborn, hemophilia, or other bleeding disorders can result in lower gastrointestinal bleeding and should be considered in this age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INFANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of bleeding in infancy (1 month to 2 years) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anorectal fissures",
"     </li>",
"     <li>",
"      Milk or soy-induced enterocolitis (allergic colitis)",
"     </li>",
"     <li>",
"      Intussusception",
"     </li>",
"     <li>",
"      Meckel's diverticulum",
"     </li>",
"     <li>",
"      Hemolytic uremic syndrome and Henoch-Sch&ouml;nlein purpura (HSP, also called IgA vasculitis [IgAV])",
"     </li>",
"     <li>",
"      Lymphonodular hyperplasia",
"     </li>",
"     <li>",
"      Gastrointestinal duplication",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anal fissures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal fissures are discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Anorectal fissures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Milk- or soy-induced colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk or soy-induced colitis is an inflammatory enteropathy caused by ingestion of milk or soy proteins, and occurs almost exclusively in infants. It can also occur in breast-fed infants because of maternally ingested cow's milk protein. Affected infants have loose stools, often with occult or gross blood but are otherwise healthy. Up to 25 percent of patients with cow's milk protein intolerance will have a cross-reaction to soy protein. Treatment involves elimination of the causative protein from the mother&rsquo;s diet if the infant is breastfed, or the use of a casein-hydrolysate formula. The intolerance usually resolves by 1 year of age, at which time an unrestricted diet can be resumed. Food protein-induced enteropathy and enterocolitis syndrome are separate but related disorders, in which vomiting rather than rectal bleeding is the prominent feature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intussusception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intussusception is the most common cause of intestinal obstruction in infants between 6 and 36 months of age. Approximately 60 percent of children are younger than 1 year old, and 80 percent are younger than 2. In this age group, intussusception usually is idiopathic and occurs in the ileocecal region, in contrast to older children in whom a polyp or Meckel's diverticulum may serve as a lead point.",
"   </p>",
"   <p>",
"    Patients usually are awakened from sleep with severe abdominal pain, which causes them to be irritable and draw up their legs. They vomit and may pass a stool and improve temporarily before the cycle repeats. Eventually, patients become apathetic and pale, and may pass a bloody, mucoid stool. A sausage-shaped mass in the distribution of the colon, typically in the area of the transverse colon, may be palpable on abdominal examination. The stool contains gross or occult blood in most but not all cases.",
"   </p>",
"   <p>",
"    Ultrasonography is the method of choice to detect intussusception in most institutions. The diagnosis can also be established with a contrast enema, which also can reduce the intussusception in 75 to 90 percent of children. The choice among these procedures varies with the experience of the radiologist.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and management of intussusception are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Meckel's diverticulum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meckel's diverticulum results from incomplete obliteration of the omphalomesenteric duct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=see_link&amp;anchor=H15#H15\">",
"     \"Care of the umbilicus and management of umbilical disorders\", section on 'Omphalomesenteric duct anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rule of twos best describes Meckel's diverticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/15\">",
"     15",
"    </a>",
"    ]. It occurs in 2 percent of the population with a male-to-female ratio of 2:1, is found within two feet of the ileocecal valve, and is two inches long. Approximately 2 percent develop a complication over the course of their lives. There is probably no familial predisposition for Meckel's diverticulum, although a few cases of occurrence within the same family have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meckel's diverticulum is usually asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/17\">",
"     17",
"    </a>",
"    ]. Sixty percent of patients having complications are younger than 2 years of age. Bleeding usually is painless and results from mucosal ulceration within ectopic gastric tissue. One-half of Meckel's diverticula do not have gastric mucosa and are therefore not associated with bleeding.",
"   </p>",
"   <p>",
"    The diagnosis is made by a Meckel scan. The scan consists of the intravenous administration of 99m technetium pertechnetate, which has an affinity for gastric mucosa, followed by scintigraphy to identify areas of ectopic gastric mucosa. The accuracy of a Meckel scan is improved by administration of H2 blockers 24 to 48 hours before the test. A symptomatic Meckel's diverticulum should be resected. An asymptomatic Meckel's diverticulum discovered incidentally at laparotomy in children are usually also resected. However, whether such asymptomatic lesions should be resected in adults is controversial because of the low incidence of complications in older patients who have never had symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2458?source=see_link\">",
"     \"Meckel&rsquo;s diverticulum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hemolytic uremic syndrome and Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic-uremic syndrome and Henoch-Sch&ouml;nlein purpura (HSP, also called IgA vasculitis [IgAV]) are syndromes that may present with rectal bleeding. Up to 50 percent of patients with HSP (IgAV) have guaiac-positive stools. Accompanying clinical features of palpable cutaneous purpura, swelling of the feet, and joint pains usually permit easy diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemolytic-uremic syndrome is characterized by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury. Most cases are associated with an infection with an enteropathogen producing a shiga-like toxin, such as E. Coli, in which case diarrhea is a prominent feature and is frequently bloody. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lymphonodular hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphonodular hyperplasia is a common finding in infants and young children who undergo endoscopy of the intestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The etiology is unknown. Some consider it to be a normal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] whereas others believe it to be an immunologic response to a variety of stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ]. It occurs frequently in children with food protein induced colitis, in whom it may be an abnormal finding at colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Milk- or soy-induced colitis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because lymphonodular hyperplasia disrupts the normal mucosa, it leads to mucosal thinning and predisposes to ulceration, which may cause hematochezia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/19\">",
"     19",
"    </a>",
"    ]. Blood loss is usually minimal and painless but is present in multiple stools [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/26\">",
"     26",
"    </a>",
"    ]. Lymphonodular hyperplasia resolves spontaneously over time, and is an unlikely source of bleeding in children older than 7 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Gastrointestinal duplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal duplications can be found at any level of the gastrointestinal tract and usually do not communicate with the bowel lumen. Gastric mucosa (present in approximately 50 percent of duplications) can ulcerate, perforate, and form fistulas. Formation of a gastric duplication-colonic fistula is unusual but can result in a lower GI bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PRESCHOOL PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of lower gastrointestinal bleeding in the preschool period (ages two to five years) are infections and polyps. Anal fissures also are common, especially in children with constipation, and are usually distinguishable from other causes of lower gastrointestinal bleeding by history and physical examination. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Anorectal fissures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Infectious diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pathogens can cause lower gastrointestinal bleeding in preschool children, Campylobacter, Shigella, Escherichia coli, Salmonella, Yersinia, Clostridium difficile, and Entamoeba histolytica. Neisseria gonorrhea, Chlamydia trachomatis, and Herpes simplex virus (HSV) also occasionally produce bloody stools. Infection should be considered in children presenting with bleeding accompanied by dysenteric symptoms (eg, fever, abdominal pain, tenesmus, small volume bloody stools). (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    The diagnosis of an infectious etiology is made by isolating the organism from the stool or blood. Other ancillary tests such as occult blood, fecal leukocytes, or fecal lactoferrin are nonspecific, although in one study, lactoferrin appeared to be the most accurate of the three assays [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Shigellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigellosis occurs most commonly in children between 1 and 4 years of age. Patients typically present with fever, abdominal pain, and watery diarrhea that becomes bloody. The total white blood cell count (WBC) may be normal or markedly elevated, but the differential usually shows a greater band count than segmented neutrophils. Untreated, the disease typically lasts for 7 to 10 days, but organism carriage can continue for as long as three weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic therapy for five days eradicates the organism from the gastrointestinal tract, reduces the intensity and duration of the illness, and limits the likelihood of spread to other contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/29\">",
"     29",
"    </a>",
"    ]. The choice of therapy is complicated by widespread resistance to common agents such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    in many parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In children acquiring the infection in the United States, TMP-SMX is usually the drug of first choice although susceptibility testing should be performed. For infections acquired in other parts of the world, a third-generation cephalosporin should probably be chosen since quinolone therapy usually is avoided in children.",
"   </p>",
"   <p>",
"    Potential complications from shigellosis are intestinal perforation, toxic megacolon, dehydration, sepsis, hyponatremia and hypoglycemia, pneumonia, hemolytic uremic syndrome (HUS), and seizures or encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/32\">",
"     32",
"    </a>",
"    ]. The impact of antibiotic therapy on reducing the occurrence and severity of these complications is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Salmonellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salmonella gastroenteritis occurs most commonly in children younger than 5 years of age and has its highest incidence in the first year, during which it is accompanied by bacteremia in approximately 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/33\">",
"     33",
"    </a>",
"    ]. A larger inoculum is needed to produce infection compared to Shigella. Blood is a less common finding in the stool with Salmonella compared to Shigella. The WBC is variable but may have a left shift. Although of unproven benefit, antimicrobial therapy is indicated for patients younger than 3 months and other children at risk at increased risk for invasive disease, including those with malignancies, hemoglobinopathies, chronic gastrointestinal tract disease, and immunocompromised states including human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Choices of antibiotics include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , TMP-SMX,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . Antimicrobial therapy is not indicated for patients with uncomplicated (noninvasive) gastroenteritis caused by nontyphoidal Salmonella species because therapy does not shorten the duration of the disease and can prolong the duration of excretion of Salmonella organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Campylobacter",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. jejuni usually produces a dysenteric syndrome in patients up to 8 years of age. It is isolated with equal frequency to Salmonella and Shigella. Most cases will resolve spontaneously within two weeks. A five- to seven-day course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    eliminates the organism from the stool in two to three days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Escherichia coli",
"    </span>",
"    &nbsp;&mdash;&nbsp;E. coli is an important cause of food-borne diarrheal illness and can occur in clusters of cases. The most serious complication is the development of HUS from infection with the enterohemorrhagic E. coli O157:H7. Early antibiotic administration may increase the risk of developing HUS, perhaps because of enhanced toxin release as the bacteria are killed. This possibility was demonstrated in a prospective study of 71 children younger than the age of 10 years with E. coli O157:H7 isolated from stool; those receiving antibiotics were more likely to develop HUS (56 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"     \"Pathogenic Escherichia coli\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Yersinia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yersinia gastroenteritis is associated with bloody stools in 25 percent of patients. In addition to a dysenteric syndrome, it causes an acute ileitis, which mimics appendicitis and Crohn disease. Most cases resolve spontaneously within two weeks, and the benefit of antimicrobial treatment remains unproven except for reduced excretion. Y. enterocolitica is resistant to first-generation cephalosporins and penicillins.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    , aminoglycosides,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    (avoid in patients younger than 8 years), and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    are the recommended choices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Clostridium difficile",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. difficile enteritis usually occurs after exposure to antibiotics, especially",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and the cephalosporins. However, community-associated infection with a highly toxigenic strain of Clostridium difficile has been reported in otherwise healthy children who had minimal or no exposure to antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H14#H14\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical disease varies from mild diarrhea to a dysenteric syndrome. Diagnosis is made by the detection of C. difficile toxin by enzyme-linked immunosorbent assay in the stool. Stool culture for C. difficile does not differentiate toxin- from nontoxin-producing strains, and up to 50 percent of healthy neonates and infants can be colonized with this organism. The colonization rate decreases to less than 5 percent in children older than the age of 2 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If possible, antibiotics should be stopped or changed in affected patients. If diarrhea persists or if toxicity is present, oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is indicated for 7 to 10 days. Intravenous metronidazole may be considered in the severely ill patient; parenteral vancomycin is not effective because it does not achieve intraluminal concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Other organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult or overt bleeding can occur as a result of infection with N. gonorrhoeae, C. trachomatis and HSV. Sexual abuse should be considered in children when these organisms are recovered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Juvenile polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile polyps are benign hamartomas, which occur between the ages of 2 and 8 years, with a peak at 3 to 4 years. Patients usually present with painless rectal bleeding, although a few may have lower abdominal pain from traction on the polyp. More than 60 percent of patients have a palpable polyp by rectal examination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polyps are confined to the rectosigmoid region in 80 to 90 percent of cases, with almost 75 percent being in the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/37\">",
"     37",
"    </a>",
"    ]. Juvenile polyps in the rectum tend to autoamputate or on occasion present as prolapsed tissue. Polyps usually bleed after injury by fecal passage and usually result in bright red blood on the outside of the stool; if the polyp is located proximally, the blood will be darker and found in the core of the stool.",
"   </p>",
"   <p>",
"    Diagnostic methods that have been used include double-contrast enemas following bowel preparation, hydrocolonic ultrasound (ultrasound after a warm saline enema) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/38\">",
"     38",
"    </a>",
"    ], sigmoidoscopy (rigid and flexible) and colonoscopy. The first two methods are capable of diagnosis only and should be reserved as screening tools in circumstances in which colonoscopy is not readily available. Sigmoidoscopy is useful in the diagnosis and treatment of most juvenile polyps but would miss proximal polyps, which occur in as many as 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonoscopy is the best way to diagnose polyps and permits their immediate painless removal under mild sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/39\">",
"     39",
"    </a>",
"    ]. All polyps should be removed. Most children have only one or two juvenile polyps, and in this case follow-up examinations are not necessary because recurrence after polypectomy is uncommon (&lt;5 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, patients with three or more juvenile polyps (especially &gt;10 polyps) and those with a family history of polyps may have familial juvenile polyposis or juvenile polyposis syndrome. These patients should undergo colonoscopy and biopsy every few years to exclude colorectal neoplasia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759704#H21759704\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Juvenile polyposis syndrome and familial juvenile polyposis'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SCHOOL-AGED CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of disorders in school-aged children with lower gastrointestinal bleeding is similar to that of the preschool children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17730768\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, inflammatory bowel disease (IBD) often presents in school-aged children and adolescents. The most common presentation of IBD is diarrhea (with or without blood), occurring in 80 percent of patients with Crohn disease and 100 percent of patients with ulcerative colitis. The diagnosis usually is suspected by the chronicity of symptoms and weight loss or growth failure (especially in those with Crohn disease), and many patients have iron deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated erythrocyte sedimentation rate. Some patients with IBD may have extraintestinal symptoms, including anorexia, arthralgia and erythema nodosum. The diagnosis is confirmed with colonoscopy and biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with inflammatory bowel disease or familial polyposis have some risk for developing malignancy, but colon cancer is still rare in the pediatric age group. Colon cancer in children without these underlying conditions has been described in only a few case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29513/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H32\">",
"     'Juvenile polyps'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18017873\">",
"    <span class=\"h1\">",
"     RARE CAUSES OF LOWER GI BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare causes of lower gastrointestinal bleeding in children and adolescents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular malformations &ndash; eg, associated with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"       \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adenomatous polyps &ndash; Patients with adenomatous polyps should be further evaluated for familial adenomatous polyposis or one of its variants because of a high risk of developing colorectal cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"       \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastrointestinal stromal tumors (GIST) &ndash; GIST are often associated with Carney&rsquo;s syndrome (GIST, pulmonary chondromas, paraganglioma, adrenal cortical adenoma, and esophageal leiomyoma). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link&amp;anchor=H1013925#H1013925\">",
"       \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Pediatric GIST'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Solitary rectal ulcer syndrome &ndash; This is a benign but chronic ulcerative disease of the rectum that is rare in childhood. It tends to present with bleeding, passage of mucus, straining during defecation, and a sense of incomplete evacuation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21125?source=see_link\">",
"       \"Solitary rectal ulcer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Typhlitis &ndash; Typhlitis is an enterocolitis of the ileocecal region that occurs in patients with neutropenia, most commonly in children with hematologic malignancies. It presents with fever and abdominal pain, and sometimes with bloody diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=see_link\">",
"       \"Typhlitis (neutropenic enterocolitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/22/43361?source=see_link\">",
"       \"Patient information: Meckel&rsquo;s diverticulum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17729389\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    The major causes of lower gastrointestinal bleeding in infants and children vary by age group (",
"    <a class=\"graphic graphic_figure graphicRef58363 \" href=\"UTD.htm?37/30/38382\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants, important causes include: (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Infancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anorectal fissures and infectious colitis (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Anal fissures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Milk- or soy-induced proctocolitis, in which the infant is usually healthy except for blood-tinged loose stools (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Milk- or soy-induced colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intussusception, which is characterized by abrupt onset of severe crampy abdominal pain, often with vomiting or lethargy; most patients have gross or occult rectal bleeding. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Intussusception'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In preschool-aged children, important causes include: (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Preschool period'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intussusception, anorectal fissures, and infectious colitis, as in infants",
"     </li>",
"     <li>",
"      Hemolytic-uremic syndrome (triggered by certain enteric infections) or Henoch-Sch&ouml;nlein purpura (HSP, also called IgA vasculitis [IgAV) (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Hemolytic uremic syndrome and Henoch-Sch&ouml;nlein purpura (IgA vasculitis)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Juvenile polyps",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In school-aged children and adolescents, important causes include: (See",
"      <a class=\"local\" href=\"#H33\">",
"       'School-aged children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anorectal fissures, infectious colitis, and juvenile polyps, as in pre-school aged children",
"     </li>",
"     <li>",
"      Inflammatory bowel disease (See",
"      <a class=\"local\" href=\"#H17730768\">",
"       'Inflammatory bowel disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/1\">",
"      Teach SJ, Fleisher GR. Rectal bleeding in the pediatric emergency department. Ann Emerg Med 1994; 23:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/2\">",
"      Khurana AK, Saraya A, Jain N, et al. Profile of lower gastrointestinal bleeding in children from a tropical country. Trop Gastroenterol 1998; 19:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/3\">",
"      Dupont C, Badoual J, Le Luyer B, et al. Rectosigmoidoscopic findings during isolated rectal bleeding in the neonate. J Pediatr Gastroenterol Nutr 1987; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/4\">",
"      Perisic VN. Colorectal polyps: an important cause of rectal bleeding. Arch Dis Child 1987; 62:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/5\">",
"      Cucchiara S, Guandalini S, Staiano A, et al. Sigmoidoscopy, colonoscopy, and radiology in the evaluation of children with rectal bleeding. J Pediatr Gastroenterol Nutr 1983; 2:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/6\">",
"      Silber G. Lower gastrointestinal bleeding. Pediatr Rev 1990; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/7\">",
"      Morrow RJ, Lawson N, Hussaini SH, Asquith P. The usefulness of faecal haemoglobin, albumin and alpha-1-antitrypsin in the detection of gastrointestinal bleeding. Ann Clin Biochem 1990; 27 ( Pt 3):208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/8\">",
"      Moran A, Lawson N, Morrow R, et al. Value of faecal alpha-1-antitrypsin, haemoglobin and a chemical occult blood test in the detection of gastrointestinal disease. Clin Chim Acta 1993; 217:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/9\">",
"      Littenberg B. Stool collection for occult blood testing. Ann Intern Med 1988; 109:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/10\">",
"      SPENCER R. GASTROINTESTINAL HEMORRHAGE IN INFANCY AND CHILDHOOD: 476 CASES. Surgery 1964; 55:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/11\">",
"      Rodgers BM. Upper gastrointestinal hemorrhage. Pediatr Rev 1999; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/12\">",
"      Liu N, Wu AH, Wong SS. Improved quantitative Apt test for detecting fetal hemoglobin in bloody stools of newborns. Clin Chem 1993; 39:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/13\">",
"      O'Hara SM. Acute gastrointestinal bleeding. Radiol Clin North Am 1997; 35:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/14\">",
"      Teitelbaum DH, Cilley RE, Sherman NJ, et al. A decade of experience with the primary pull-through for hirschsprung disease in the newborn period: a multicenter analysis of outcomes. Ann Surg 2000; 232:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/15\">",
"      Pollack ES. Pediatric abdominal surgical emergencies. Pediatr Ann 1996; 25:448.",
"     </a>",
"    </li>",
"    <li>",
"     Passarge E, Stevenson RE. Meckel's diverticulum. In: Human malformations and related anomalies, 2nd, Stevenson RE, Hall JE (Eds), Oxford University Press, Oxford 2006. p.1111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/17\">",
"      Park JJ, Wolff BG, Tollefson MK, et al. Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950-2002). Ann Surg 2005; 241:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/18\">",
"      Zani A, Eaton S, Rees CM, Pierro A. Incidentally detected Meckel diverticulum: to resect or not to resect? Ann Surg 2008; 247:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/19\">",
"      Kaplan B, Benson J, Rothstein F, et al. Lymphonodular hyperplasia of the colon as a pathologic finding in children with lower gastrointestinal bleeding. J Pediatr Gastroenterol Nutr 1984; 3:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/20\">",
"      Kokkonen J, Karttunen TJ. Lymphonodular hyperplasia on the mucosa of the lower gastrointestinal tract in children: an indication of enhanced immune response? J Pediatr Gastroenterol Nutr 2002; 34:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/21\">",
"      Franken EA Jr. Lymphoid hyperplasia of the colon. Radiology 1970; 94:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/22\">",
"      Riddlesberger MM Jr, Lebenthal E. Nodular colonic mucosa of childhood: normal or pathologic? Gastroenterology 1980; 79:265.",
"     </a>",
"    </li>",
"    <li>",
"     Tuck D, Michaud L. Lower gastrointestinal bleeding. In: Pediatric Gastrointestinal Disease, 4th, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker Inc, Hamilton, Ontario 2004. p.266.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/24\">",
"      Chiche A, Gottrand F, Turck D, et al. [Proctorrhagia secondary to lymphonodular hyperplasia revealing a food allergy]. Arch Fr Pediatr 1990; 47:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/25\">",
"      Iacono G, Ravelli A, Di Prima L, et al. Colonic lymphoid nodular hyperplasia in children: relationship to food hypersensitivity. Clin Gastroenterol Hepatol 2007; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/26\">",
"      Col&oacute;n AR, DiPalma JS, Leftridge CA. Intestinal lymphonodular hyperplasia of childhood: patterns of presentation. J Clin Gastroenterol 1991; 13:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/27\">",
"      Mahnovski V, Mahour GH, Rowland JM. Gastric duplication-colonic fistula with colonic ulceration and bleeding. J Pediatr Surg 1998; 33:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/28\">",
"      Huicho L, Campos M, Rivera J, Guerrant RL. Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview. Pediatr Infect Dis J 1996; 15:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/29\">",
"      Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis 1991; 13 Suppl 4:S332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/30\">",
"      Replogle ML, Fleming DW, Cieslak PR. Emergence of antimicrobial-resistant shigellosis in Oregon. Clin Infect Dis 2000; 30:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/31\">",
"      Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992; 14:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/32\">",
"      Bennish ML. Potentially lethal complications of shigellosis. Rev Infect Dis 1991; 13 Suppl 4:S319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/33\">",
"      Torrey S, Fleisher G, Jaffe D. Incidence of Salmonella bacteremia in infants with Salmonella gastroenteritis. J Pediatr 1986; 108:718.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Salmonella infections. In: Red Book: 2012 Report of the committee on infectious diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, et al.  (Eds), American Academy of Pediatrics, Elk Grove, IL 2012. p.635.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/35\">",
"      Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/36\">",
"      Balkan E, Kiritiolu I, G&uuml;rpinar A, et al. Sigmoidoscopy in minor lower gastrointestinal bleeding. Arch Dis Child 1998; 78:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/37\">",
"      Poddar U, Thapa BR, Vaiphei K, Singh K. Colonic polyps: experience of 236 Indian children. Am J Gastroenterol 1998; 93:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/38\">",
"      Nagita A, Amemoto K, Yoden A, et al. Ultrasonographic diagnosis of juvenile colonic polyps. J Pediatr 1994; 124:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/39\">",
"      Latt TT, Nicholl R, Domizio P, et al. Rectal bleeding and polyps. Arch Dis Child 1993; 69:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/40\">",
"      Khan AM, Doig CM, Dickson AP. Advanced colonic carcinoma in children. Postgrad Med J 1997; 73:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29513/abstract/41\">",
"      Kravarusic D, Feigin E, Dlugy E, et al. Colorectal carcinoma in childhood: a retrospective multicenter study. J Pediatr Gastroenterol Nutr 2007; 44:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5904 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-DD2D800F1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29513=[""].join("\n");
var outline_f28_52_29513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17729389\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CAUSES OF BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NEONATAL PERIOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Swallowed maternal blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Apt test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anorectal fissures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Necrotizing enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Malrotation with midgut volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INFANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anal fissures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Milk- or soy-induced colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intussusception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Meckel's diverticulum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hemolytic uremic syndrome and Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lymphonodular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Gastrointestinal duplication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PRESCHOOL PERIOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Infectious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Shigellosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Campylobacter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Yersinia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Clostridium difficile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Other organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Juvenile polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SCHOOL-AGED CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17730768\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18017873\">",
"      RARE CAUSES OF LOWER GI BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17729389\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5904|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/30/38382\" title=\"figure 1\">",
"      Causes LGI bleeding children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/23/5499\" title=\"table 1\">",
"      False positive visible blood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=related_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=related_link\">",
"      Care of the umbilicus and management of umbilical disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=related_link\">",
"      Clostridium difficile infection in children: Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=related_link\">",
"      Clostridium difficile infection in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=related_link\">",
"      Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=related_link\">",
"      Clostridium difficile infection in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=related_link\">",
"      Evaluation of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20232?source=related_link\">",
"      Intestinal malrotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2458?source=related_link\">",
"      Meckel&rsquo;s diverticulum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=related_link\">",
"      Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/22/43361?source=related_link\">",
"      Patient information: Meckel&rsquo;s diverticulum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21125?source=related_link\">",
"      Solitary rectal ulcer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27125?source=related_link\">",
"      Typhlitis (neutropenic enterocolitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_52_29514="Treatment of opioid abuse and dependence";
var content_f28_52_29514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of opioid abuse and dependence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29514/contributors\">",
"     Michael F Weaver, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29514/contributors\">",
"     John A Hopper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29514/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/52/29514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/52/29514/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/52/29514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid dependence is a chronic, relapsing illness. Patients with opioid dependence who have gone through the acute withdrawal period from opioids have completed only the first step toward successful long-term recovery. Long-term maintenance treatment is typically needed; treatment options include non-medication, abstinence-based treatment, or medication maintenance with opioid agonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    ) and opioid antagonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Opioids subject to abuse and dependence include heroin, a principally illicit drug, and prescription opioids diverted to nonmedical use. Maintenance treatment for opioid dependence often takes place in specialized treatment programs, but the role of the primary care clinician in pharmacologic maintenance therapy has expanded in some countries, including the United States (US), since the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    for office-based treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term treatment for opioid dependence is reviewed here. An overview of opioid abuse and dependence, and the initial patient evaluation, are discussed separately. The management of acute opioid intoxication and withdrawal, and the management of addiction in medical professionals, are also discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"     \"Opioid withdrawal in the emergency setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"     \"Opioid detoxification during treatment for addiction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5562?source=see_link\">",
"     \"Impaired healthcare provider\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266080\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term treatment of opioid dependence can take several forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opioid agonist treatment &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      (or, in selected countries, heroin administered in a controlled setting) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Methadone'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Buprenorphine'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H23\">",
"       'Heroin maintenance programs'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Opioid antagonist treatment &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       Naltrexone",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H8932613\">",
"       'Naltrexone'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Abstinence-based treatment &mdash; A non-pharmacologic treatment that can include various psychosocial services (eg, individual and group counseling, peer support groups such as Narcotics Anonymous, and residential treatment) without medication. (see",
"      <a class=\"local\" href=\"#H267421111\">",
"       'Psychosocial treatments'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on the efficacy of individual medications and other treatments for opioid dependence are presented below; data comparing treatments are described thereafter. (See",
"    <a class=\"local\" href=\"#H265894\">",
"     'Treatment selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266257\">",
"    <span class=\"h1\">",
"     MAINTENANCE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance medications for opioid dependence include opioid antagonists and opioid agonists. Treatment with an antagonist prevents the user from experiencing recreational effects with subsequent opioid use, and therefore helps to extinguish continued opioid use and reinforces abstinence. Opioid agonists, alternatively, suppress craving and withdrawal symptoms.",
"   </p>",
"   <p>",
"    Patients who receive an opioid agonist no longer have to spend time searching for illicit heroin or attempting to obtain prescription narcotics for abuse, and can return to a productive lifestyle. As examples, they can safely operate machinery and drive without significant impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/2\">",
"     2",
"    </a>",
"    ]. Agonist therapy is not equivalent to addiction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . Although they are physically dependent upon methadone or buprenorphine, patients are more likely to refrain from abusing other drugs. Some patients remain on opioid maintenance for many years, while others have been tapered off agonist therapy. After discussion with a program counselor, a patient may elect to undergo detoxification by very slow tapering of the dose over several months to years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    , a long-acting opioid agonist, binds and blocks opioid receptors, reducing the euphoric effects of subsequent opioid abuse. As a controlled substance with potential for abuse and dependence, methadone use is regulated in the US and other countries. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Regulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 1969 participants in 11 randomized trials compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy to placebo or non-medication treatment for opioid dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients receiving methadone were more likely to remain in treatment and to reduce opioid use compared to placebo or non-medication treatment. Methadone maintenance treatment has been associated with reductions in the spread of human immunodeficiency virus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], and in some studies, with reduced criminal behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a trial randomly assigned 247 participants with opioid dependence and cocaine abuse to 20 weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    treatment, the latter 15 weeks of which at stable doses of 50 mg, 20 mg, or 0 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/8\">",
"     8",
"    </a>",
"    ]. All three groups additionally received individual counseling and group therapy. By treatment week 20, retention was 52.4 percent for the 50 mg group, 41.5 percent for the 20-mg group, and 21.0 percent for the 0 mg group. The 50 mg treatment group had a reduced rate of opioid-positive urine samples compared to the 0 mg group (56.4 versus 73.6 percent), while the 20 mg group showed no difference compared to the 0 mg group.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    treatment may reduce mortality from opioid dependence. A 10-year follow up study of 405 patients randomly assigned to receive either methadone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    found an association between the duration of treatment with either medication and lower rates of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is regulated by many countries including the US, where it is classified as a Schedule II drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link&amp;anchor=H268753597#H268753597\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\", section on 'Regulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3345622\">",
"    <span class=\"h4\">",
"     US regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only licensed opioid treatment programs or licensed inpatient hospital detoxification units in the US are permitted to prescribe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for withdrawal or long-term treatment of drug dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outpatient treatment programs, known as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance clinics, are required to provide counseling and social services in addition to methadone. Patients are required to attend individual counseling sessions at least two times per month or groups sessions weekly. (See",
"    <a class=\"local\" href=\"#H267421111\">",
"     'Psychosocial treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to these federal regulations, many states have imposed additional restrictions on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for opioid dependence. In contrast, methadone can be prescribed for treatment of acute or chronic pain in the US by any clinician with a Drug Enforcement Administration license.",
"   </p>",
"   <p>",
"    To be eligible for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance in the US, a prospective patient must have:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical dependence on opioids for at least one year of continuous use or intermittent use spanning a longer period of time. Exceptions to this criterion include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who have been on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance within the past two years do not need to demonstrate current physical dependence if the program clinician documents a likelihood of an imminent return to opioid dependence.",
"     </li>",
"     <li>",
"      Patients recently released from incarceration or hospitalization do not need to show current dependence but are required to have a history of physical dependence and have a clinician document a likelihood of relapse to dependence.",
"     </li>",
"     <li>",
"      Pregnant women are eligible for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance even if dependent for less than one year, if a return to dependence is likely during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An age of 18 years or older. Younger individuals are eligible for treatment &mdash; with the consent of a parent, guardian, or designated responsible adult &mdash; if they have current physical dependence and have at least two previous attempts at detoxification or psychosocial substance abuse treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    in the US distinguishes between use of methadone for opioid detoxification, which is defined as methadone treatment for less than 180 days, and methadone maintenance, which is defined as the use of methadone for more than 180 days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/10\">",
"     10",
"    </a>",
"    ]. Some patients may elect to undergo detoxification by supervised, slow tapering, while others remain on a stable dose indefinitely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients do best on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    doses between 80 to 120",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which is typically sufficient to block a euphoric response if patients self-administer additional opioids. Methadone dosing for opioid addiction differs significantly from doses used in the treatment of pain.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is usually administered in a single daily dose. Some clinics may offer &ldquo;split dosing&rdquo;, provided twice daily (eg, in cases of pregnancy or rapid methadone metabolism).",
"   </p>",
"   <p>",
"    In the US and other countries,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    is provided in a controlled setting with direct observation of ingestion by clinic personnel to prevent diversion of methadone and reduce the risk of overdose.",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance treatment may vary based on the time of the last opioid use, the amount used, and whether the patient has developed a reduction in tolerance to opioids (eg, patients who were recently released from incarceration or hospitalization may have significantly reduced tolerance).",
"   </p>",
"   <p>",
"    A typical initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for opioid addiction is 20 to 30 mg. Methadone is typically given as a liquid, often diluted with juice or water or artificially colored water. (Each client receives a full cup of uniformly colored liquid regardless of the dose of methadone in order to reduce anxiety among clients about differences in dose. The dilution and coloring is also intended to reduce the likelihood of a patient injecting &ldquo;take home&rdquo; methadone.) The dose is often titrated up over the first few days by 10 to 20 mg each day to 60 to 80 mg daily. Titration then proceeds more slowly over the next several weeks (frequently 10 mg a week) to alleviate cravings and opioid withdrawal symptoms (which are assessed daily). This gradual adjustment allows methadone to reach a pharmacologic steady state to match the patient&rsquo;s level of opioid tolerance and avoid intoxication or oversedation. The dose may be adjusted every 1 to 2 weeks by 5 to 10 mg each time based on patient assessment and feedback.",
"   </p>",
"   <p>",
"    A variety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    doses have been used for maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/11\">",
"     11",
"    </a>",
"    ]. Methadone is given in doses sufficiently high that additional doses of opioid do not cause euphoria. Several randomized trials found that patients do better on higher (80 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    rather than lower methadone doses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]; doses at these levels are not overly sedating following the development of tolerance. Patients who concurrently take benzodiazepines may be more likely to become sedated from methadone.",
"   </p>",
"   <p>",
"    Initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    should be accompanied by ongoing monitoring. There should be limited use of take-home doses (individual bottled doses of methadone to be taken outside the treatment setting, used with patients who are at low risk for diversion) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Eligibility for take-home doses is based on adherence to program requirements for counseling and abstinence from illicit drugs (based on urine toxicology testing). Patients generally need 90 days of continuous abstinence from illicit drugs to be eligible for take home doses.",
"   </p>",
"   <p>",
"    Federal regulations specify a maximum dose on day one of 30 mg in the US, although an additional 10 mg may be administered if the patient has significant withdrawal symptoms a few hours after the first dose.",
"   </p>",
"   <p>",
"    A study of 222 heroin-addicted patients seeking treatment in a VA setting, and followed for one year, found a wide range in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    doses (1.5 to 191.2 mg, median 69 mg) were needed to achieve abstinence of at least one month [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/18\">",
"     18",
"    </a>",
"    ]. Higher methadone doses were necessary in patients with depression or other psychiatric comorbidities, a greater number of previous heroin detoxifications, or living in areas where heroin was likely to be less pure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance is the treatment of choice for opioid-dependent pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/19\">",
"     19",
"    </a>",
"    ]. A stable methadone dose reduces fluctuations in maternal opioid levels, which reduces stress on the fetus. Illicitly purchased heroin is adulterated with other compounds that may be harmful to the fetus; methadone use in pregnancy reduces the risk of fetal harm from exposure to such adulterants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance also enhances the ability of the woman to participate in prenatal care and addiction treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/20\">",
"     20",
"    </a>",
"    ]. Methadone dose requirements may increase during the third trimester due to larger plasma volume, reduced protein binding, increased tissue binding, and increased metabolism. Splitting the total daily methadone dose into a morning and evening dose is preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Women can breastfeed on methadone as long as they are not abusing drugs and are not HIV infected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Use during hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient receiving maintenance treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    is hospitalized, such as for a traumatic injury or medical illness, the maintenance dose should be continued throughout hospitalization. The hospital clinician should contact the methadone maintenance program to verify the patient's current dose and to arrange for resumption of the medication after discharge",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance patients with acute pain should be treated for pain with opioid or nonopioid medications during the hospitalization, as would be appropriate if they were not on methadone. Long-term use of methadone, which reaches steady state levels in the body, does not typically provide patients with analgesia. Recommendations for selecting, dosing, and administering pain medications in patients receiving methadone for opioid dependence are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher than usual opioid analgesic doses may be required because of opioid cross tolerance, and the patient's increased pain sensitivity.",
"     </li>",
"     <li>",
"      The patient's usual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      dose should be continued, and short-acting opioid analgesics administered additionally. These should be given on a schedule, and not ordered as-needed.",
"     </li>",
"     <li>",
"      If the patient cannot take oral medication,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      can be given by the intramuscular or subcutaneous route. The parenteral dose should be given as half to two-thirds the maintenance dose, divided into two to four equal doses through the day.",
"     </li>",
"     <li>",
"      Mixed agonist and antagonist opioid analgesics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"       pentazocine",
"      </a>",
"      (Talwin),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"       nalbuphine",
"      </a>",
"      (Nubain), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"       butorphanol",
"      </a>",
"      (Stadol) should not be administered, as they may displace",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      from the mu receptor and precipitate acute withdrawal.",
"     </li>",
"     <li>",
"      Combination products with fixed doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and an opioid (such as Percocet) should be avoided for most patients, since higher opioid dose requirements may expose patients to potentially hepatotoxic doses of acetaminophen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    therapy include constipation, mild drowsiness, excess sweating, and peripheral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Reduced libido and erectile dysfunction are common among heroin users and those in treatment for opioid dependence. Methadone use is believed to contribute to this dysfunction, possibly through reduction in serum testosterone levels; however, psychological and social factors are also associated with its presence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. No significant association has been found between erectile dysfunction and methadone dose or duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360270012\">",
"    <span class=\"h4\">",
"     Cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    use, in both therapeutic doses and overdoses, has been associated with QTc interval prolongation and torsades de pointes, which in some cases has been fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/30\">",
"     30",
"    </a>",
"    ]. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/31-33\">",
"     31-33",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/34\">",
"     34",
"    </a>",
"    ] have noted a significant but weak relationship between the methadone dose and the degree of QTc prolongation at doses up to 300",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Many patients who develop torsades de pointes while taking methadone have other risk factors for this arrhythmia. Drug-induced QTc prolongation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concern regarding the proarrhythmic potential of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    prompted a physician safety alert from the Food and Drug Administration (FDA) in the US and the following recommendations by a US expert panel for patients treated with methadone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be informed of the risk of arrhythmia when they are prescribed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients should be asked about a history of structural heart disease, arrhythmia, or syncope.",
"     </li>",
"     <li>",
"      A pretreatment ECG should be obtained for all patients to measure the QTc interval. A follow-up ECG should be obtained within 30 days of treatment and annually; additional ECG monitoring is indicated for doses &ge;100 mg per day, or if the patient has unexplained syncope or seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While continued monitoring with annual follow-up ECGs is important, we would not withhold treatment in patients without a history of cardiac disease if an ECG has not been obtained",
"   </p>",
"   <p>",
"    In our clinical experience, some patients with opioid dependence have a sufficiently high risk of mortality or serious morbidity that the benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    outweigh the risks indicated by a prolonged QTC interval. [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential risks and benefits of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      therapy should be discussed with the patient for QTc interval &gt;450 msec but &lt;500 msec, and the ECG should monitored more frequently. For QTc interval &gt;500 msec, consider discontinuing or reducing the methadone dose; contributing factors (eg hypokalemia, other drugs) should be eliminated and alternative therapy considered.",
"     </li>",
"     <li>",
"      Clinicians should be aware of interactions between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      and other drugs that prolong the QTc interval or slow methadone elimination (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preliminary study suggests that substitution of (R,S)-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    with (R)-methadone reduces the methadone-induced prolonged QTc interval among opioid-dependent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/40\">",
"     40",
"    </a>",
"    ]. Further research is needed to confirm this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605393420\">",
"    <span class=\"h4\">",
"     Hyperalgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and other opioid agonists may result in an increased sensitivity to pain, which may develop within a month of initiating chronic opioid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. This may limit the utility of methadone for opioid dependent patients with chronic pain. In a study of patients in methadone treatment programs, chronic severe pain was reported in 37 percent, and 65 percent of those with pain experienced significant impact on physical and psychosocial functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605393427\">",
"    <span class=\"h4\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    appears to have a greater potential for lethal overdose compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H267421331\">",
"     'Methadone versus buprenorphine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients are at increased risk of overdose at specific stages of treatment for opioid dependence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Death during induction into",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance treatment has been reported in a series of cases from New South Wales Australia in 1994 and 1996 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/15,45\">",
"       15,45",
"      </a>",
"      ]. The overall mortality rate during methadone maintenance induction was 7.1 deaths per 10,000 inductions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/45\">",
"       45",
"      </a>",
"      ]. Benzodiazepines were significantly more likely to contribute to death both in methadone maintenance patients and in patients taking methadone for chronic pain [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who complete detoxification from opioid use are at risk of serious overdose should they resume their former drug use. One small study found that individuals who had completely detoxified from opioids were at increased risk of death from a drug overdose over the next year compared to those who did not complete detoxification [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from the US and other countries have shown a rising rate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    -related deaths over the past two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The increase in methadone-related deaths has been related to increased availability of methadone tablets used for treatment of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    maintenance treatment is associated with reduced overall mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/50\">",
"     50",
"    </a>",
"    ], with a 70 percent reduction in the risk of mortality (especially due to heroin overdose) comparing patients on methadone maintenance to untreated heroin abusers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/51\">",
"     51",
"    </a>",
"    ]. A longitudinal, observational study found a reduction in mortality of 40 percent in patients on methadone maintenance compared to predicted mortality risk prior to methadone maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/52\">",
"     52",
"    </a>",
"    ]. The reduced mortality was due to reductions in both all-cause mortality and overdose death; most overdoses were due to polysubstance intoxication in which illicit opioid use may or may not have been involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25098497\">",
"    <span class=\"h2\">",
"     Levo-alpha acetyl methadol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levo-alpha acetyl methadol (LAAM), a long-acting synthetic opioid, is no longer being manufactured due to its risk of causing cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Buprenorphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    , a partial opioid agonist, reduces illicit opioid use in long-term treatment of patients with opioid dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/13,54,55\">",
"     13,54,55",
"    </a>",
"    ]. Two formulations of buprenorphine have been developed, a sublingual tablet taken daily (described in the paragraphs that follow) and a long-acting implant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10715380\">",
"    <span class=\"h3\">",
"     US regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is the first drug that can be prescribed in a clinician's office for opioid detoxification and maintenance in the US. Buprenorphine is classified as a Schedule III controlled substance in the US. Buprenorphine may only be used by certified and specially trained clinicians who have registered with the Center for Substance Abuse Treatment (CSAT) of the Substance Abuse and Mental Health Services Administration (SAMHSA). Information on the training and registration process is available at",
"    <a class=\"external\" href=\"file://buprenorphine.samhsa.gov/\">",
"     buprenorphine.samhsa.gov",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Clinicians providing office-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    are required to refer patients for counseling. Unlike in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance programs, patients on buprenorphine are not required to receive counseling at the same treatment site. (See",
"    <a class=\"local\" href=\"#H267421111\">",
"     'Psychosocial treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Induction may be accomplished in the clinician&rsquo;s office under observation, or at the patient&rsquo;s home [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/56\">",
"     56",
"    </a>",
"    ]. When on a stable dose, patients may receive up to a one-month supply of medication with refills for up to six months, similar to other Schedule III controlled substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266585\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis that included 4497 participants in 24 randomized trials found that sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    improved treatment retention and reduced opioid use in patients with opioid dependence compared to placebo treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/57\">",
"     57",
"    </a>",
"    ]. As an example, in a four-week randomized trial of office-based treatment of 326 patients with opiate dependence, subjects who received buprenorphine (16 mg),",
"    <span class=\"nowrap\">",
"     buprenorphine/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"      naloxone",
"     </a>",
"    </span>",
"    (16",
"    <span class=\"nowrap\">",
"     mg/4",
"    </span>",
"    mg), or placebo had rates of urine screens negative for opiates of 20.8, 17.8, and 5.8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605393571\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is typically taken sublingually. It is available alone or in a combination preparation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , an opioid antagonist that has poor oral absorption. The combination is used to prevent people from abusing the drug by crushing the tablets and dissolving them for intravenous injection. Naloxone has little to no activity when administered sublingually, but would discourage intravenous buprenorphine abuse since the naloxone can precipitate withdrawal when given parenterally to opioid dependent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     buprenorphine/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"      naloxone",
"     </a>",
"     ,",
"    </span>",
"    the patient must be abstinent from other opioids for at least 24 hours to prevent precipitation of withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/59\">",
"     59",
"    </a>",
"    ]. It is best if the patient displays some early signs of opioid withdrawal at the time of induction to ensure that the patient will not develop severe withdrawal when buprenorphine displaces any other opioid from the opioid receptors.",
"   </p>",
"   <p>",
"    A typical starting dose is",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"      buprenorphine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"      naloxone",
"     </a>",
"    </span>",
"    4",
"    <span class=\"nowrap\">",
"     mg/1",
"    </span>",
"    mg given sublingually. After two hours observation, if withdrawal symptoms remain, an additional 2 to 4 mg of buprenorphine can be administered. On the following day, the patient is given a single dose consisting of the total of the doses received the first day. Following observation for residual withdrawal symptoms, the dose may be increased in 4 mg increments, up to a maximum of 16 mg total. Most patients will stabilize on 16 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of buprenorphine, so the dose should not be increased above 20 mg for several days to allow time to reach pharmacologic steady state. Some patients may need doses up to 32",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but this is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/60\">",
"     60",
"    </a>",
"    ]. Doses above 32 mg should not be given, since patients are likely to experience unpleasant opioid antagonist effects, such as jitteriness.",
"   </p>",
"   <p>",
"    When discontinued,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    should be tapered gradually. Reduce the dose by 2 mg every one to two weeks. If a more rapid taper is necessary (eg, prior to elective surgery or incarceration), the dose can be reduced by 2 mg every one to three days.",
"   </p>",
"   <p>",
"    Some patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance may be transitioned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . However, administration of buprenorphine or",
"    <span class=\"nowrap\">",
"     buprenorphine/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"      naloxone",
"     </a>",
"    </span>",
"    may precipitate an acute opioid withdrawal syndrome in patients with opioid dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Patients on methadone maintenance are generally tapered down to 30 mg or less of methadone daily before being given buprenorphine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/63\">",
"     63",
"    </a>",
"    ]. In one study, however, patients who were maintained on methadone 100 mg daily and received repeated small doses of",
"    <span class=\"nowrap\">",
"     buprenorphine/naloxone",
"    </span>",
"    did not experience significant precipitated withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    is currently the treatment of choice for opioid dependent women during pregnancy, because of the many years of experience with its use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]; however, studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    is safe and effective for both mother and newborn, with the potential for reduced severity of neonatal abstinence syndrome compared to methadone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a randomized trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    in the treatment of 175 pregnant women with opioid dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/70\">",
"     70",
"    </a>",
"    ]. Sixty-seven percent of women receiving buprenorphine and 82 percent of women receiving methadone continued treatment through the end of pregnancy. The buprenorphine-treated group required less",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (mean dose, 1.1 mg versus 10.4 mg), experienced shorter hospital stays (10.0 versus 17.5 days), and had a shorter duration of treatment for neonatal abstinence syndrome (4.1 versus 9.9 days) compared to the methadone-treated group. There were no differences between groups in adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Use during hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    who experience acute pain during hospitalization (eg, secondary to surgery) should be treated for pain with opioid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonopioid medications during the hospitalization, as would be appropriate if they were not on buprenorphine. Short-acting opiates should be dosed in higher than usual doses, on a set schedule, and mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    opioid analgesics should be avoided. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Methadone'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of chronic pain\", section on 'Opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pain management of patients maintained on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    is complicated by the high affinity of buprenorphine for the mu receptor. Potential competition between buprenorphine and full agonist opioids when both are administered concurrently places the patient at risk of opioid overdose when the antagonist is displaced. The rate of displacement of buprenorphine from the receptor is variable.",
"   </p>",
"   <p>",
"    Mild to moderate acute pain in hospitalized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    -treated patients can be managed by adding a short&ndash;acting opioid analgesic while continuing the patient's usual dose of buprenorphine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/25\">",
"     25",
"    </a>",
"    ]. With",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    available, titrate up the analgesic gradually while monitoring the patient&rsquo;s level of consciousness and respiration. Avoid abrupt discontinuation of buprenorphine.",
"   </p>",
"   <p>",
"    For pain that is severe, or that is likely to persist for a significant period of time, discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    and give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    20 to 40 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/25\">",
"     25",
"    </a>",
"    ]. Methadone dosing should be based on the patient&rsquo;s buprenorphine dose (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 3",
"    </a>",
"    ). Administer a short-acting opioid analgesic to treat pain with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    available at bedside. When pain has resolved, discontinue methadone and resume buprenorphine with an induction period. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Buprenorphine'",
"    </a>",
"    above.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605393578\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    include sedation and constipation. More severe adverse effects include respiratory depression, which is unlikely to reach a fatal level due to the partial agonist properties of buprenorphine that prevent complete activation of the mu opioid receptors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    -related deaths in patients on maintenance therapy have occurred primarily when buprenorphine is taken in combination with other substances, especially benzodiazepines and alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/71\">",
"     71",
"    </a>",
"    ] or with intravenous abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/72\">",
"     72",
"    </a>",
"    ]. Death is caused by oversedation leading to respiratory depression and hypoxia. Buprenorphine appears to have a lower potential for lethal overdose compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H267421331\">",
"     'Methadone versus buprenorphine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14978477\">",
"    <span class=\"h3\">",
"     Buprenorphine implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitations related to adherence, diversion, and nonmedical use of sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    have prompted interest in an implantable long-acting formulation. A randomized trial of 163 patients with opioid dependence compared treatment with subdermal buprenorphine implants to placebo implants over a six-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/73\">",
"     73",
"    </a>",
"    ]. Both groups received manual-based drug counseling and limited amounts of supplementary sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/51/24375?source=see_link\">",
"     buprenorphine-naloxone",
"    </a>",
"    . The group that received buprenorphine implants had a higher proportion of observed urine tests that were negative for illicit opioids compared to the placebo group (40.4 versus 28.3 percent after 16 weeks). They were also more likely to complete the study and less likely to report withdrawal symptoms or cravings. Minor implant site reactions were the most common adverse effect. Further study of the implants is needed, particularly in comparison to daily maintenance medications for opioid dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8932613\">",
"    <span class=\"h2\">",
"     Naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opioid antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    is an option for maintenance treatment to prevent relapse in opioid dependence. Naltrexone blocks the effects of opioids if they are used. Naltrexone should not be used prior to detoxification, because the drug can cause immediate withdrawal symptoms. Taken daily, naltrexone maintenance is most effective in patients who are highly motivated or legally mandated to receive treatment, and when taking the medication is closely supervised. Long-acting formulations are available for patients with difficulty adhering to daily medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1051260\">",
"    <span class=\"h3\">",
"     Oral naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    has only been found to be effective in the treatment of opioid dependence when adherence is enforced. A meta-analysis of 1158 participants in 13 randomized trials compared oral naltrexone maintenance treatment to either placebo or non-medication treatment. No difference was seen between the two groups in sustained abstinence or most other primary outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/74\">",
"     74",
"    </a>",
"    ]. Trials were limited by poor adherence and high dropout rates. Oral naltrexone was more effective than placebo in sustaining abstinence in three trials where patients were forced to adhere to daily doses of the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    is taken as a single 50 mg tablet once daily, starting after detoxification from opioids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8932687\">",
"    <span class=\"h3\">",
"     Long-acting naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    is available in injectable-depot and implantable formulations, both administered in monthly doses in a physician&rsquo;s office. Depot naltrexone is dosed individually by the compounding manufacturer based on the patient&rsquo;s weight. Implantable naltrexone is a compounded product that typically consists of a 1.4 gram pellet that is injected subcutaneously every 60 to 90 days, although protocols vary.",
"   </p>",
"   <p>",
"    Long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    has been found to be more effective than placebo in opioid dependence in randomized trials, although trials were limited by high dropout rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. One trial found the drug to be efficacious in patients dependent on more than one drug, a common presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomly assigned 60 patients with heroin dependence to receive injectable depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      (at doses of 384 or 192 mg) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/75\">",
"       75",
"      </a>",
"      ]. The medication and placebo were administered at four week intervals. At the end of two months, retention in treatment was greater in both treatment groups (higher and lower dose) than in the placebo group (68 and 60 percent versus 39 percent). Treatment resulted in negative urine drug tests in a greater proportion of patients treated with depot naltrexone group compared to 25 percent of the placebo group (62 versus 25 percent). However, when missing urine tests were considered to be positive for opioids, no differences in urine drug tests were seen between groups. Adverse events were minimal and generally mild.",
"     </li>",
"     <li>",
"      A trial compared a once-monthly, injectable depot formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      to placebo in 250 patients with opioid dependence over 24 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/76\">",
"       76",
"      </a>",
"      ]. The median proportion of weeks of confirmed abstinence was 90 percent in the actively treated group compared to 35 percent in the placebo group; however, these findings exclude 47 percent of the patients who did not complete the study.",
"     </li>",
"     <li>",
"      A trial in 100 heroin and amphetamine-dependent outpatients compared the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      implants to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/77\">",
"       77",
"      </a>",
"      ]. After ten weeks of treatment, patients in the naltrexone group had higher retention in the study (52 versus 28 percent), a higher proportion of urine samples free of heroin and amphetamines (38 versus 16 percent), and a higher rate of clinically significant improvement on the clinical global impressions scale, compared to the placebo group. The investigators&rsquo; decision to classify missed urine screens as positive, combined with the higher proportion of drop outs in the placebo group, may have resulted in a lower rate of heroin-free urine samples in the placebo group than was actually present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8932701\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common side effects include nausea. In the event of acute pain requiring treatment with an opioid analgesic, a higher dose will be needed to overcome the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    blockade of opioid receptors. More severe adverse effects include liver damage, but this is rare.",
"   </p>",
"   <p>",
"    Patients who discontinue antagonist therapy and resume opioid use should be made aware of the risk of serious overdose. This may be due to loss of tolerance to opioids and a resulting misjudgment of dose at the time of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Heroin maintenance programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several countries, including Switzerland and the Netherlands, have instituted programs that include provision of injectable heroin prescriptions to addicted individuals who have failed other maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An open-label, randomized trial compared injectable diacetylmorphine (the active ingredient in heroin) with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy in 226 patients with treatment-refractory opioid dependence in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/81\">",
"     81",
"    </a>",
"    ]. Patients treated with diacetylmorphine were more likely to remain in addiction treatment after one year (87.8 versus 54.1 percent) and experienced a greater reduction in illegal activity, including illicit drug use (67.0 versus 47.7 percent). A relatively high incidence of serious adverse events, including ten overdoses and six seizures, among patients receiving diacetylmorphine suggests the drug should be administered in a medically supervised setting.",
"   </p>",
"   <p>",
"    A study of the Swiss program found a reduction in the risk of infection with hepatitis B and C viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/82\">",
"     82",
"    </a>",
"    ], decreased heroin use, and early entry (within two years) of users into",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    substitution programs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/79\">",
"     79",
"    </a>",
"    ]. It is hypothesized that the \"medicalization\" of heroin use made it less attractive for young people. A Dutch study suggested a cost utility benefit for heroin co-prescription in treatment-resistant heroin users, with program costs offset by lower estimated costs for law enforcement and damage to victims of crime [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of opiate dependence with heroin remains controversial. Potential risks of heroin injection programs, including adverse events, drug substitution, drug diversion, and co-addiction, need further study and should be weighed against growing evidence of efficacy, from both a societal and patient perspective. Practices are likely to continue to differ by country, as attitudes toward drug treatment are influenced by culture as well as research evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267421111\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of psychosocial treatments for opioid dependence has not been sufficiently tested. A meta-analysis of 27 trials found that adding specific, structured psychosocial interventions to medication treatment of opioid dependence did not yield advantages over more general psychosocial treatment, but trials have not evaluated whether any ancillary psychosocial treatment was superior to medication treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/85\">",
"     85",
"    </a>",
"    ]. A National Institutes of Health Consensus Conference in the US concluded that &ldquo;non-pharmacologic supportive services are pivotal to successful treatment&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychosocial treatment for maintenance treatment of opioid dependence includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Individual and group drug counseling &mdash; Drug counseling is a broadly used term to describe individual and group therapies that include education and may incorporate elements of cognitive behavioral therapy and insight-oriented psychotherapies as well .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specific psychosocial interventions &mdash; A systematic review of five randomized trials testing psychosocial interventions for opioid abuse and dependence (Contingency Management, Brief Reinforcement Based Intensive Outpatient Therapy coupled with Contingency Management, Cue Exposure therapy, Alternative Program for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      Maintenance Treatment Program Drop-outs, and Enhanced Outreach-Counselling Program) did not find sustained benefits from the interventions compared to a control condition [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/87\">",
"       87",
"      </a>",
"      ]. These studies had methodological limitations; well-designed trials of psychosocial interventions for opioid dependence are needed [",
"      <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug-free residential programs &mdash; Residential programs can be oriented toward providing transitional support between detoxification and outpatient treatment, or toward longer-term treatment for individuals with opioid dependence who have not responded to treatment at less intensive levels of care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2936?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical management of substance dependence across the continuum of care\", section on 'Residential care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some treatment programs for opioid dependence are philosophically opposed to the use of medications, especially agonist therapies for maintenance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peer support groups &mdash; Peer support groups (eg, Narcotics Anonymous) generally focus on helping group members to achieve and maintain abstinence from drugs such as opioids. Group members help one another recognize and overcome behaviors associated with their addiction. Peer support groups for opioid dependence have not been tested in clinical trials. In our clinical experience, many patients report benefiting from participation in these groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients taking medication to treat opioid dependence may feel stigmatized by others in peer support groups such as Narcotics Anonymous. Treatment programs sponsoring these groups may want to advise patients to focus their sharing within the group on the addiction rather than on approaches to treatment. Alternatively, patients may wish to seek out specific groups that view pharmacotherapy favorably.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    Anonymous is such a program, available in some geographic areas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional services, such as job skills development, housing assistance, and legal services",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Psychosocial interventions can serve as standalone maintenance treatment for opioid dependence (ie, abstinence-based treatment) or can be combined with medication maintenance treatment. (See",
"    <a class=\"local\" href=\"#H4918139\">",
"     'Combined medication and psychosocial treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267421118\">",
"    <span class=\"h2\">",
"     Abstinence-based treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abstinence-based treatment for opioid dependence is a non-medication approach to maintenance treatment that follows the completion of detoxification. Basic components of abstinence based treatment include individual psychosocial counseling and participation in a peer-support program. Abstinence-based treatment can be delivered in an outpatient or residential setting.",
"   </p>",
"   <p>",
"    There are few controlled trials of abstinence-based treatment in patients with opioid dependence, and those conducted have significant methodologic limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. As an example, a six-month trial randomly assigned 168 patients with opioid dependence &mdash; abstinent following either detoxification or discharge from a abstinence-based residential program &mdash; to a weekly abstinence-based, outpatient group relapse prevention program and weekly peer support meetings or to a control condition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/88\">",
"     88",
"    </a>",
"    ]. The relapse prevention group reported less opioid use and showed somewhat higher rates of employment compared to the control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265894\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data to inform clinical decisions among treatments for opioid dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265901\">",
"    <span class=\"h2\">",
"     Pharmacotherapy versus abstinence-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, we suggest maintenance treatment of opioid dependence with medication over abstinence-based therapy. Clinical trials have found that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    led to increased treatment retention and reduced opioid use compared to placebo. There are no such trials for abstinence-based therapy, nor are there trials directly comparing medication and non-medication treatment. (See",
"    <a class=\"local\" href=\"#H266257\">",
"     'Maintenance medications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H267421118\">",
"     'Abstinence-based treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Abstinence-based therapy is a reasonable alternative to pharmacotherapy in selected patients who prefer treatment without medication and voluntarily seek treatment. Patient factors supporting the choice of abstinence-based treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Greater motivation for treatment",
"     </li>",
"     <li>",
"      Shorter duration of addiction",
"     </li>",
"     <li>",
"      Smaller amounts of opioid consumption",
"     </li>",
"     <li>",
"      Prior treatment experience",
"     </li>",
"     <li>",
"      Few comorbid medical and psychiatric conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4918684\">",
"    <span class=\"h2\">",
"     Opioid antagonist versus agonist treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although trials directly comparing these interventions are unavailable, comparison of the efficacy of these approaches against control conditions strongly suggest that agonist maintenance treatment (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    ) is more efficacious than antagonist maintenance (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    ) or drug counseling without agonist therapy for most patients in opioid dependence. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Methadone'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Buprenorphine'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8932613\">",
"     'Naltrexone'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H267421111\">",
"     'Psychosocial treatments'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who are highly motivated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    under circumstances where administration can be supervised, treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    (an opioid antagonist) is feasible, but not recommended. If a patient insists on antagonist-based therapy, there should be discussion about reconsidering agonist treatment if antagonist treatment is not successful. Oral naltrexone has been found to be effective only when adherence is enforced [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1051260\">",
"     'Oral naltrexone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some occupations (which may include workers involved with public safety, transport of hazardous materials, and medical professionals) do not allow workers to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and, in some cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . Opioid antagonists do not generally face such restrictions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267421331\">",
"    <span class=\"h2\">",
"     Methadone versus buprenorphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    in opioid dependence. Buprenorphine is a reasonable alternative among patients with a history of methadone abuse or patients who prefer to receive treatment at an office-based practice rather than a methadone clinic. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Methadone'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Buprenorphine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    are both effective at reducing opioid misuse and promoting retention in treatment. A meta-analysis of 24 randomized trials comparing maintenance treatment with methadone versus buprenorphine for opioid dependence concluded that methadone was more effective than buprenorphine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/91\">",
"     91",
"    </a>",
"    ]. Results varied by dosing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trials using flexible dosing strategies found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      to be less effective compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      in retaining patients in treatment, but found no difference between groups in reduced heroin use.",
"     </li>",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      resulted in greater treatment retention than low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      No difference was seen between medium-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      in treatment retention, but buprenorphine showed some evidence of superior suppression of heroin use.",
"     </li>",
"     <li>",
"      No difference was seen between medium-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      and medium-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      in treatment retention; methadone was more effective in suppressing heroin use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    (maximum daily dose 8 mg sublingual) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance (up to 80 mg) found that more patients receiving methadone continued therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/92\">",
"     92",
"    </a>",
"    ]. However, of patients who completed the study, those taking buprenorphine had significantly lower rates of illicit opioid consumption. Similar results have been reported by others, suggesting that maintenance with this agent may be most useful in highly motivated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    may be safer than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    when considered from the perspective of potential abuse of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/94\">",
"     94",
"    </a>",
"    ]. Doses of methadone used for treatment of opioid dependence exceed the lethal dose (50 mg) for opioid-naive adults. Because it is a partial agonist, buprenorphine has a lower potential for causing respiratory depression than methadone, and the typical treatment dose (16 to 32 mg) can be tolerated by opioid-naive users.",
"   </p>",
"   <p>",
"    A study of 16,434 individuals with opioid dependence treated with medication had a fourfold greater rate of mortality from overdose associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    treatment compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10715648\">",
"    <span class=\"h2\">",
"     Short-acting versus long-acting medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have problems with adherence to daily medication treatment for opioid dependence, we suggest treatment with long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    . A trial compared a single administration of a naltrexone implant (2.3 g; plus pill placebo) to oral naltrexone (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for six months in 70 patients with heroin dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/96\">",
"     96",
"    </a>",
"    ]. Patients receiving naltrexone implants were less likely to have returned to regular heroin use by six months and returned later (158 versus 115 days) compared to patients receiving oral naltrexone. (See",
"    <a class=\"local\" href=\"#H8932687\">",
"     'Long-acting naltrexone'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4918139\">",
"    <span class=\"h2\">",
"     Combined medication and psychosocial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are treated with medication for opioid dependence, we suggest adjunctive treatment with individual or group drug counseling and participation in a peer support program such as Narcotics Anonymous. Although such combined treatment has not been shown to result in improved outcomes over medication alone, in our clinical experience, counseling and peer support programs can improve adherence to treatment and contribute to prevention of relapse. (See",
"    <a class=\"local\" href=\"#H267421111\">",
"     'Psychosocial treatments'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A meta-analysis of 35 randomized trials of 13 structured psychosocial interventions (eg, contingency management) in patients with opioid dependence found no difference in treatment retention or opioid abstinence when comparing patients who received a psychosocial intervention plus maintenance medication versus patients who received maintenance medication alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/85\">",
"     85",
"    </a>",
"    ]. These trials did not test the combination of medication with routine, non-structured counseling; in fact, a limitation of these trials was that patients in the &ldquo;medication-only&rdquo; control groups often received counseling.",
"   </p>",
"   <p>",
"    Regulatory requirements in the US and other countries require that patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    receive psychosocial treatment and patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    receive a referral to such treatment. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Regulation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Buprenorphine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266831\">",
"    <span class=\"h2\">",
"     Stepped care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stepped care approach to treatment of opioid dependence has been evaluated in Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?28/52/29514/abstract/97\">",
"     97",
"    </a>",
"    ]. In a randomized trial, 96 patients with heroin dependence were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or to stepped treatment initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    and escalated to methadone if needed; both groups were additionally treated with behavioral therapy. Buprenorphine was dosed at 16 mg at day 3, and titrated as needed to a maximum of 32 mg daily. Methadone was titrated to 70 mg by day 10, to a maximum of 120",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    A treatment retention rate of 78 percent was achieved in both groups, while the percentage of opiate-free urine samples ultimately reached approximately 80 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=see_link\">",
"       \"Patient information: Prescription drug abuse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients dependent on opioids often require maintenance treatment to prevent relapse. Treatment options include non-medication, abstinence-based treatment or long-term medication maintenance with opioids, or opioid antagonists. (See",
"      <a class=\"local\" href=\"#H266080\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest maintenance treatment of opioid dependence with medication over abstinence-based therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients who prefer a non-medication approach can be provided abstinence-based treatment consisting of individual psychosocial counseling and participation in a peer support program (eg, Narcotics Anonymous or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      Anonymous). (See",
"      <a class=\"local\" href=\"#H266257\">",
"       'Maintenance medications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H267421118\">",
"       'Abstinence-based treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients who prefer a daily oral medication, and are not likely to adhere to treatment with an opioid antagonist, in general we suggest treatment with an opioid agonist, specifically, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Most patients do best on methadone doses between 80 to 120",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      which is typically sufficient to block a euphoric response if they self-administer additional opioids. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Methadone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Buprenorphine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H267421331\">",
"       'Methadone versus buprenorphine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    is suggested for patients who have access to clinical settings that prescribe the medication as well as to drug counseling services. In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , the medication and counseling services do not need to be provided by the same program or site in the US. Candidates for buprenorphine should be reliable enough and have a sufficiently supportive home environment to adhere to treatment at an office-based setting.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    should be taken in a combined formulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    (Suboxone) to discourage abuse. Buprenorphine can be started at 4 mg (with 1 mg of naloxone), sublingually. Most patients will stabilize on 16 to 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    <br/>",
"    <br/>",
"    Buprenorphine is suggested for patients at risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    overdose (eg, with a history of methadone abuse or recent, enforced abstinence, such as in prison or in a hospital) and patients with prolonged QT intervals on ECG.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are highly motivated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      under circumstances where administration can be supervised, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      (an opioid antagonist) over an opioid agonist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Oral naltrexone is taken as a single 50 mg tablet once daily. Long-acting naltrexone can be used in patients who have problems with adherence to daily medications. (See",
"      <a class=\"local\" href=\"#H4918684\">",
"       'Opioid antagonist versus agonist treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1051260\">",
"       'Oral naltrexone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8932687\">",
"       'Long-acting naltrexone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      programs who require hospitalization for pain or surgery should be maintained on their usual methadone dose and given additional short-acting opioid analgesia on a scheduled dose. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Use during hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parenteral heroin administration has been effective in treatment-resistant patients in a randomized trial; however, concerns remain about risks and benefits. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Heroin maintenance programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are treated with medication for opioid dependence, we suggest adjunctive treatment with individual or group counseling and participation in a peer support program such as Narcotics Anonymous (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4918139\">",
"       'Combined medication and psychosocial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H267421111\">",
"       'Psychosocial treatments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/1\">",
"      Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004; 164:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/2\">",
"      Hauri-Bionda R, B&auml;r W, Friedrich-Koch A. [Driving fitness/driving capacity of patients treated with methadone]. Schweiz Med Wochenschr 1998; 128:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/3\">",
"      Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003; :CD002209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/4\">",
"      Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/5\">",
"      Novick DM, Joseph H, Croxson TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/6\">",
"      Gowing LR, Farrell M, Bornemann R, et al. Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/7\">",
"      Nurco DN, Ball JC, Shaffer JW, Hanlon TE. The criminality of narcotic addicts. J Nerv Ment Dis 1985; 173:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/8\">",
"      Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/9\">",
"      Gibson A, Degenhardt L, Mattick RP, et al. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008; 103:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/10\">",
"      Federal Register: Methadone: Rules and regulations. The Federal Register 1989; 544:8954.",
"     </a>",
"    </li>",
"    <li>",
"     Senay, EC. Opioids: Methadone maintenance. In: Galanter, M, Kleber, HD (Eds), Textbook of Substance Abuse Treatment, 2nd ed, American Psychiatric Press, Inc., Washington, DC 1999. p. 271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/12\">",
"      Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/13\">",
"      Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/14\">",
"      Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; :CD002208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/15\">",
"      Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/16\">",
"      Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002; 26:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/17\">",
"      Zador DA, Sunjic SD. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug Alcohol Rev 2002; 21:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/18\">",
"      Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual opioid-dependent patients. PLoS Med 2006; 3:e80.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Substance Abuse Treatment (CSAT). Pregnant, substance-abusing women (treatment improvement protocol 2). CSAT, Substance Abuse and Mental Health Services Administration, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     Weaver, M. Perinatal addiction. In: Graham, AW, and Shultz, TK (Eds), Principles of addiction medicine, 3rd ed, American Society of Addiction Medicine, Inc, Chevy Chase, MD 2003. p.1231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/21\">",
"      Wittmann BK, Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991; 26:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/22\">",
"      Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999; 18:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/23\">",
"      McCarthy JJ, Posey BL. Methadone levels in human milk. J Hum Lact 2000; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/24\">",
"      Geraghty B, Graham EA, Logan B, Weiss EL. Methadone levels in breast milk. J Hum Lact 1997; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/25\">",
"      Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/26\">",
"      O'Conor LM, Woody G, Yeh HS, et al. Methadone and edema. J Subst Abuse Treat 1991; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/27\">",
"      Kleber HD. Treatment of narcotic addicts. Psychiatr Med 1985; 3:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/28\">",
"      Brown R, Balousek S, Mundt M, Fleming M. Methadone maintenance and male sexual dysfunction. J Addict Dis 2005; 24:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/29\">",
"      Quaglio G, Lugoboni F, Pattaro C, et al. Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug Alcohol Depend 2008; 94:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/30\">",
"      Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/31\">",
"      Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/32\">",
"      Martell BA, Arnsten JH, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003; 139:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/33\">",
"      Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/34\">",
"      Peles E, Bodner G, Kreek MJ, et al. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 2007; 102:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/35\">",
"      Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/36\">",
"      Byrne A. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:216; author reply 218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/37\">",
"      Cohen SP, Mao J. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/38\">",
"      Girgis G. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/39\">",
"      Bart G. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Ann Intern Med 2009; 151:218; author reply 218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/40\">",
"      Ansermot N, Albayrak O, Schl&auml;pfer J, et al. Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch Intern Med 2010; 170:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/41\">",
"      Pud D, Cohen D, Lawental E, Eisenberg E. Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend 2006; 82:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/42\">",
"      Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/43\">",
"      Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/44\">",
"      Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/45\">",
"      Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000; 95:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/46\">",
"      Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/47\">",
"      Webster LR. Methadone-related deaths. J Opioid Manag 2005; 1:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/48\">",
"      Williamson PA, Foreman KJ, White JM, Anderson G. Methadone-related overdose deaths in South Australia, 1984-1994. How safe is methadone prescribing? Med J Aust 1997; 166:302.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Substance Abuse Treatment (CSAT). Methadone-associated mortality: Report of a National Assessment. CSAT Pub. No. 28-03. Substance Abuse and Mental Health Services Administration, Rockville, MD 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/50\">",
"      Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000; 22:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/51\">",
"      Desmond, DP, Maddux, JF. Deaths among heroin users in and out of methadone treatment. J Maint Addict 2000; 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/52\">",
"      Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008; 94:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/53\">",
"      Wieneke H, Conrads H, Wolstein J, et al. Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial. Eur J Med Res 2009; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/54\">",
"      Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003; :CD002207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/55\">",
"      Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/56\">",
"      Gunderson EW, Wang XQ, Fiellin DA, et al. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010; 35:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/57\">",
"      Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004; :CD002207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/58\">",
"      Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/59\">",
"      Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/60\">",
"      Fareed A, Vayalapalli S, Casarella J, Drexler K. Treatment outcome for flexible dosing buprenorphine maintenance treatment. Am J Drug Alcohol Abuse 2012; 38:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/61\">",
"      Strain EC, Preston KL, Liebson IA, Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 1995; 272:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/62\">",
"      Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70:S13.",
"     </a>",
"    </li>",
"    <li>",
"     McNicholas, L. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. US Department of Health and Human Services 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/64\">",
"      Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend 2007; 90:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/65\">",
"      Fischer G. Treatment of opioid dependence in pregnant women. Addiction 2000; 95:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/66\">",
"      ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/67\">",
"      Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003; 70:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/68\">",
"      Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/69\">",
"      Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/70\">",
"      Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/71\">",
"      Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/72\">",
"      Byrne A. Reducing deaths among drug misusers. Standard of care in Britain was not addressed. BMJ 2001; 323:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/73\">",
"      Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010; 304:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/74\">",
"      Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; :CD001333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/75\">",
"      Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/76\">",
"      Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/77\">",
"      Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012; 169:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/78\">",
"      Rehm J, Gschwend P, Steffen T, et al. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001; 358:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/79\">",
"      Nordt C, Stohler R. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. Lancet 2006; 367:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/80\">",
"      van den Brink W, Hendriks VM, Blanken P, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003; 327:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/81\">",
"      Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/82\">",
"      Steffen T, Bl&auml;ttler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001; 11:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/83\">",
"      Dijkgraaf MG, van der Zanden BP, de Borgie CA, et al. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 2005; 330:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/84\">",
"      Berridge V. Heroin prescription and history. N Engl J Med 2009; 361:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/85\">",
"      Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011; :CD004147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/86\">",
"      Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/87\">",
"      Mayet S, Farrell M, Ferri M, et al. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2005; :CD004330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/88\">",
"      McAuliffe WE. A randomized controlled trial of recovery training and self-help for opioid addicts in New England and Hong Kong. J Psychoactive Drugs 1990; 22:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/89\">",
"      Bale RN, Van Stone WW, Kuldau JM, et al. Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one-year follow-up. Arch Gen Psychiatry 1980; 37:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/90\">",
"      Bale RN, Zarcone VP, Van Stone WW, et al. Three therapeutic communities. A prospective controlled study of narcotic addiction treatment: process and two-year follow-up results. Arch Gen Psychiatry 1984; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/91\">",
"      Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; :CD002207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/92\">",
"      Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/93\">",
"      Eder H, Fischer G, Gombas W, et al. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998; 4 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/94\">",
"      Luty J, O'Gara C, Sessay M. Is methadone too dangerous for opiate addiction? BMJ 2005; 331:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/95\">",
"      Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/96\">",
"      Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 2009; 66:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/52/29514/abstract/97\">",
"      Kakko J, Gr&ouml;nbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007; 164:797.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7803 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29514=[""].join("\n");
var outline_f28_52_29514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266080\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266257\">",
"      MAINTENANCE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Methadone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Regulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3345622\">",
"      US regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Use during hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H360270012\">",
"      Cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H605393420\">",
"      Hyperalgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H605393427\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25098497\">",
"      Levo-alpha acetyl methadol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Buprenorphine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10715380\">",
"      - US regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H266585\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H605393571\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Use during hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H605393578\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14978477\">",
"      - Buprenorphine implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8932613\">",
"      Naltrexone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1051260\">",
"      - Oral naltrexone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8932687\">",
"      - Long-acting naltrexone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8932701\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Heroin maintenance programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267421111\">",
"      PSYCHOSOCIAL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267421118\">",
"      Abstinence-based treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265894\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265901\">",
"      Pharmacotherapy versus abstinence-based therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4918684\">",
"      Opioid antagonist versus agonist treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267421331\">",
"      Methadone versus buprenorphine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10715648\">",
"      Short-acting versus long-acting medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4918139\">",
"      Combined medication and psychosocial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266831\">",
"      Stepped care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 1\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11760\" title=\"table 3\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2936?source=related_link\">",
"      Clinical management of substance dependence across the continuum of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5562?source=related_link\">",
"      Impaired healthcare provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=related_link\">",
"      Patient information: Prescription drug abuse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_52_29515="Odds of Down syndrome after a positive screening test";
var content_f28_52_29515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Odds of Down syndrome after a positive test result based on data from the SURUSS trial",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        First plus second trimester",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Integrated",
"       </td>",
"       <td>",
"        1 in 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum integrated",
"       </td>",
"       <td>",
"        1 in 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Second trimester",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quadruple",
"       </td>",
"       <td>",
"        1 in 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triple",
"       </td>",
"       <td>",
"        1 in 49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Double",
"       </td>",
"       <td>",
"        1 in 68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        First trimester",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Combined",
"       </td>",
"       <td>",
"        1 in 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NT",
"       </td>",
"       <td>",
"        1 in 94",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     These odds are obtained when each test is used to achieve an 85 percent detection rate.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wald, NJ, Rodeck, C, Hackshaw, AK, Rudnicka, A. BJOG 2004; 111:521.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29515=[""].join("\n");
var outline_f28_52_29515=null;
var title_f28_52_29516="NSAID dose for medical therapy";
var content_f28_52_29516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested dosages for medical therapy of dysmenorrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Initial dose, mg",
"      </td>",
"      <td class=\"subtitle1\">",
"       Subsequent dose in mg, as needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Acetic acids (Type I)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Indomethacin",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       25 tid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tolmetin",
"      </td>",
"      <td>",
"       400",
"      </td>",
"      <td>",
"       400 tid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sulindac",
"      </td>",
"      <td>",
"       200",
"      </td>",
"      <td>",
"       200 bid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diflunisal",
"      </td>",
"      <td>",
"       1000",
"      </td>",
"      <td>",
"       500 every 12 h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diclofenac",
"      </td>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       75 bid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Etodolac",
"      </td>",
"      <td>",
"       400",
"      </td>",
"      <td>",
"       400 every 6-8 h (maximum dose 1200 mg/24 h)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ketoralac",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       10 every 4-6 h (maximum dose 40 mg/24 h)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Propionic acids (Type I)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ibuprofen",
"      </td>",
"      <td>",
"       400",
"      </td>",
"      <td>",
"       400 every 6 h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Naproxen",
"      </td>",
"      <td>",
"       500",
"      </td>",
"      <td>",
"       250 every 6-8 h (maximum dose 1250 mg/24 h)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Naproxen sodium",
"      </td>",
"      <td>",
"       550",
"      </td>",
"      <td>",
"       275 every 6-8 h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fenoprofen calcium",
"      </td>",
"      <td>",
"       200",
"      </td>",
"      <td>",
"       200 every 4-6 h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ketoprofen",
"      </td>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       75 tid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Fenamates (Type I)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mefenamic acid",
"      </td>",
"      <td>",
"       500",
"      </td>",
"      <td>",
"       250 every 4 h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Meclofenamate",
"      </td>",
"      <td>",
"       100",
"      </td>",
"      <td>",
"       50-100 every 6 h",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Oxicans (Type II)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Piroxicam",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       20 once a day",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     bid: twice a day; tid: three times a day.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Smith, R. Obstet Gynecol Clin North Am 1993; 761.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29516=[""].join("\n");
var outline_f28_52_29516=null;
var title_f28_52_29517="HRCT patterns in ILD";
var content_f28_52_29517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51094%7EPULM%2F64841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51094%7EPULM%2F64841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HRCT patterns in interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiolitis obliterans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asbestosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Distribution of disease within the lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Peripheral lung zone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asbestosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bronchiolitis obliterans with organizing pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Central disease (bronchovascular thickening)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphangitic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Upper zone predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pulmonary histiocytosis X (eosinophilic granuloma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic infectious diseases (eg, tuberculosis, histoplasmosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pneumoconiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Silicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Berylliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Coal miners' pneumoconiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lower zone predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rheumatoid arthritis (associated with usual interstitial pneumonia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asbestosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HRCT patterns in interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Airspace opacities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Haze or ground glass attenuation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Desquamative interstitial pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Respiratory bronchiolitis-associated interstitial lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Drug toxicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Pulmonary hemorrhage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Lung consolidation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chronic or acute eosinophilic pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cryptogenic organizing pneumonia (bronchiolitis obliterans with organizing pneumonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Aspiration (lipoid pneumonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Alveolar carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lymphoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Alveolar proteinosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Reticular opacities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic pulmonary fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asbestosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Connective tissue disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Nodules",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersensitivity pneumonitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory bronchiolitis-associated interstitial lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary langerhans cell histiocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Silicosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coal workers' pneumoconiosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metastatic cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Isolated lung cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary langerhans cell histiocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphangioleiomyomatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic Pneumocystis carnii (P. jirovecii) pneumonia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29517=[""].join("\n");
var outline_f28_52_29517=null;
var title_f28_52_29518="Antineutrophil antibody assay";
var content_f28_52_29518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Antineutrophil antibody assay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the indirect method used to assay for antineutrophil antibodies in a patient with suspected drug-associated immune neutropenia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Young, NS, JAMA 1994; 271:935.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29518=[""].join("\n");
var outline_f28_52_29518=null;
var title_f28_52_29519="Red imported fire ant";
var content_f28_52_29519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solenopsis invicta worker (red imported fire ant)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from American Academy of Allergy and Immunology, Monograph on Insect Allergy, 3rd edition, Levine MI, Lockey RF (Eds), 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_52_29519=[""].join("\n");
var outline_f28_52_29519=null;
       